=== Generating (published_papers) ===
=== Generating (teaching_experience) ===
=== Generating (misc) ===
=== Generating (research_projects) ===
=== Generating (books_etc) ===
=== Generating (committee_memberships) ===
=== Generating (awards) ===
=== Generating (association_memberships) ===
=== Generating (presentations) ===
EID=466276 is rejected. (Reason: タイトルが登録されていません．)
EID=466276 is rejected. (Reason: タイトルが登録されていません．)
==== begin registerFile(/WWW/pub2/data/ERD/person/229265/researchmap/published_papers-propagate.jsonl) ====
line:1, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2013785","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/39557586","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85209793738","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=446871","label":"url"}],"paper_title":{"en":"Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction.","ja":"Elotuzumab-mediated ADCC with Th1-like Vγ9Vδ2 T cells to disrupt myeloma-osteoclast interaction."},"authors":{"en":[{"name":"Inoue Yusuke"},{"name":"Tenshin Hirofumi"},{"name":"Teramachi Jumpei"},{"name":"Sumitani Ryohei"},{"name":"Oda Asuka"},{"name":"Maeda Yusaku"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Maruhashi Tomoko"},{"name":"Takahashi Mamiko"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Hara Tomoyo"},{"name":"Endo Itsuro"},{"name":"Kagawa Kumiko"},{"name":"Ozaki Shuji"},{"name":"Hiasa Masahiro"},{"name":"Harada Takeshi"},{"name":"Abe Masahiro"}],"ja":[{"name":"Inoue Yusuke"},{"name":"天眞 寛文"},{"name":"Teramachi Jumpei"},{"name":"住谷 龍平"},{"name":"Oda Asuka"},{"name":"前田 悠作"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"Maruhashi Tomoko"},{"name":"Takahashi Mamiko"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"原 倫世"},{"name":"遠藤 逸朗"},{"name":"賀川 久美子"},{"name":"尾崎 修治"},{"name":"日浅 雅博"},{"name":"原田 武志"},{"name":"Abe Masahiro"}]},"description":{"en":"Multiple myeloma (MM) cells and osteoclasts (OCs) activate with each other to cause drug resistance. Human Th1-like Vγ9Vδ2 (γδ) T cells, important effectors against tumors, can be expanded and activated ex vivo by the aminobisphosphonate zoledronic acid in combination with IL-2. We previously reported that the expanded γδ T cells effectively targeted and killed OCs as well as MM cells. Because the expanded γδ T cells expressed CD16 on their surface, we investigated the utilization of the expanded γδ T cells for antibody-dependent cellular cytotoxicity (ADCC). Although the expanded γδ T cells alone induced cell death in MM cell lines, the addition of the anti-SLAMF7 monoclonal antibody elotuzumab (ELO) further enhanced their cytotoxic activity only against SLAMF7-expressing MM cell lines and primary MM cells. Intriguingly, ELO was also able to enhance γδ T cell-induced cell death against OCs cultured alone, and against both MM cells and OCs in their coculture settings. SLAMF7 was found to be highly expressed in OCs differentiated in vitro from monocytes by receptor activator of nuclear factor-κ B ligand and M-CSF, although monocytes only marginally expressed SLAMF7. These results demonstrate that SLAMF7 is highly expressed in both MM cells and OCs, and that the ex vivo-expanded γδ T cells can exert ELO-mediated ADCC against SLAMF7-expressing MM cells and OCs besides their direct cytotoxic activity. Further study is warranted for the innovative utilization of γδ T cells.","ja":"Multiple myeloma (MM) cells and osteoclasts (OCs) activate with each other to cause drug resistance. Human Th1-like Vγ9Vδ2 (γδ) T cells, important effectors against tumors, can be expanded and activated ex vivo by the aminobisphosphonate zoledronic acid in combination with IL-2. We previously reported that the expanded γδ T cells effectively targeted and killed OCs as well as MM cells. Because the expanded γδ T cells expressed CD16 on their surface, we investigated the utilization of the expanded γδ T cells for antibody-dependent cellular cytotoxicity (ADCC). Although the expanded γδ T cells alone induced cell death in MM cell lines, the addition of the anti-SLAMF7 monoclonal antibody elotuzumab (ELO) further enhanced their cytotoxic activity only against SLAMF7-expressing MM cell lines and primary MM cells. Intriguingly, ELO was also able to enhance γδ T cell-induced cell death against OCs cultured alone, and against both MM cells and OCs in their coculture settings. SLAMF7 was found to be highly expressed in OCs differentiated in vitro from monocytes by receptor activator of nuclear factor-κ B ligand and M-CSF, although monocytes only marginally expressed SLAMF7. These results demonstrate that SLAMF7 is highly expressed in both MM cells and OCs, and that the ex vivo-expanded γδ T cells can exert ELO-mediated ADCC against SLAMF7-expressing MM cells and OCs besides their direct cytotoxic activity. Further study is warranted for the innovative utilization of γδ T cells."},"publication_date":"2024-11-18","publication_name":{"en":"Cancer Science","ja":"Cancer Science"},"volume":"116","number":"2","starting_page":"559","ending_page":"563","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/cas.16401"],"issn":["1349-7006"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:2, {"insert":{"user_id":"B000341201","type":"published_papers","id":"47364775"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2012309","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38569748","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=412144","label":"url"}],"paper_title":{"en":"Skeletal muscle mass during chemotherapy for haematological malignancies: a retrospective study.","ja":"Skeletal muscle mass during chemotherapy for haematological malignancies: a retrospective study."},"authors":{"en":[{"name":"Takahashi Mamiko"},{"name":"Kondo Shin"},{"name":"Kagawa Kumiko"},{"name":"Nakamura Masafumi"},{"name":"Maeda Yusaku"},{"name":"Sumitani Ryohei"},{"name":"Yagi Hikaru"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Endo Itsuro"},{"name":"Abe Masahiro"},{"name":"Nakamura Shingen"}],"ja":[{"name":"Takahashi Mamiko"},{"name":"Kondo Shin"},{"name":"賀川 久美子"},{"name":"Nakamura Masafumi"},{"name":"Maeda Yusaku"},{"name":"住谷 龍平"},{"name":"Yagi Hikaru"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"遠藤 逸朗"},{"name":"安倍 正博"},{"name":"中村 信元"}]},"description":{"en":"This study investigated whether baseline or alteration in muscle mass affects complications during chemotherapy or overall survival (OS) in haematological malignancies. Skeletal Muscle Index (SMI) was evaluated by bioimpedance analysis before and after chemotherapy in patients with haematological malignancies, and the association between muscle mass and clinical data was retrospectively analysed. Exactly 104 patients were enrolled, with a mean age of 62.2 years. SMI was 7.85 and 6.08 in male and female patients under 65 years and 7.10 and 5.92 over 65 years, before chemotherapy, respectively. Lower baseline SMI was not correlated with worse OS in total patients (p=0.915). After a median measurement interval of 30 days after chemotherapy (n=67), body weight and SMI decreased by 2.73% and 2.87% (mean), respectively. The decrease in body weight correlated with the loss of trunk muscle mass (R=0.2107) but was more strongly associated with the loss of lower limbs muscle mass (R=0.3985). The muscle mass of lower limbs significantly decreased in lymphoma patients who experienced febrile neutropenia (-0.42% vs -6.04%, p=0.040). OS significantly decreased in lymphoma patients with loss of lower limbs muscle ≥2.8% (p=0.0327). Muscle loss occurred following anticancer treatments, significantly contributing to worse outcomes. Body composition assessment and relevant multimodal prevention of muscle loss may be vital for patients receiving chemotherapy for haematological malignancies.","ja":"This study investigated whether baseline or alteration in muscle mass affects complications during chemotherapy or overall survival (OS) in haematological malignancies. Skeletal Muscle Index (SMI) was evaluated by bioimpedance analysis before and after chemotherapy in patients with haematological malignancies, and the association between muscle mass and clinical data was retrospectively analysed. Exactly 104 patients were enrolled, with a mean age of 62.2 years. SMI was 7.85 and 6.08 in male and female patients under 65 years and 7.10 and 5.92 over 65 years, before chemotherapy, respectively. Lower baseline SMI was not correlated with worse OS in total patients (p=0.915). After a median measurement interval of 30 days after chemotherapy (n=67), body weight and SMI decreased by 2.73% and 2.87% (mean), respectively. The decrease in body weight correlated with the loss of trunk muscle mass (R=0.2107) but was more strongly associated with the loss of lower limbs muscle mass (R=0.3985). The muscle mass of lower limbs significantly decreased in lymphoma patients who experienced febrile neutropenia (-0.42% vs -6.04%, p=0.040). OS significantly decreased in lymphoma patients with loss of lower limbs muscle ≥2.8% (p=0.0327). Muscle loss occurred following anticancer treatments, significantly contributing to worse outcomes. Body composition assessment and relevant multimodal prevention of muscle loss may be vital for patients receiving chemotherapy for haematological malignancies."},"publication_date":"2024-05-17","publication_name":{"en":"BMJ Supportive & Palliative Care","ja":"BMJ Supportive & Palliative Care"},"volume":"14","number":"2","starting_page":"195","ending_page":"199","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/spcare-2024-004870"],"issn":["2045-4368"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:3, {"insert":{"user_id":"B000341201","type":"published_papers","id":"46782334"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2012299","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38813140","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85193252659","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=412140","label":"url"}],"paper_title":{"en":"Humoral immune response against SARS-CoV-2 and polyethylene glycol elicited by anti-SARS-CoV-2 mRNA vaccine, and effect of pre-existing anti-polyethylene glycol antibody in patients with hematological and autoimmune diseases.","ja":"Humoral immune response against SARS-CoV-2 and polyethylene glycol elicited by anti-SARS-CoV-2 mRNA vaccine, and effect of pre-existing anti-polyethylene glycol antibody in patients with hematological and autoimmune diseases."},"authors":{"en":[{"name":"Hori Taiki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Okada Naoto"},{"name":"Yamagami Hiroki"},{"name":"Yasui Saya"},{"name":"Hosoki Minae"},{"name":"Tojima Akihiro"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Aihara Ken-ichi"},{"name":"Takishita Makoto"},{"name":"Yoshida Sumiko"},{"name":"Abe Masahiro"},{"name":"Ishida Tatsuhiro"},{"name":"Nakamura Shingen"}],"ja":[{"name":"堀 太貴"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"岡田 直人"},{"name":"山上 紘規"},{"name":"Yasui Saya"},{"name":"Hosoki Minae"},{"name":"Tojima Akihiro"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"粟飯原 賢一"},{"name":"Takishita Makoto"},{"name":"吉田 守美子"},{"name":"安倍 正博"},{"name":"石田 竜弘"},{"name":"中村 信元"}]},"description":{"en":"The effects of vaccination are modified by hematological and autoimmune diseases and/or treatment. Anti-SARS-CoV-2 mRNA vaccine contains polyethylene glycol (PEG), it is largely unknown whether PEG influences the effects of vaccination or induces a humoral response. This study examined whether anti-PEG antibodies before vaccination (pre-existing) influenced the acquisition of SARS-CoV-2 antibodies and evaluated the relationship between the development of anti-SARS-CoV-2 antibodies and anti-PEG antibodies after SARS-CoV-2 vaccination in hematological and autoimmune diseases. Anti-SARS-CoV-2 antibody IgG, anti-PEG IgG, and IgM titers were evaluated in patients with hematological and autoimmune diseases after the second dose of BNT162B2. Anti-PEG IgG and IgM titers were also measured before vaccination to examine changes after vaccination and the relationship with vaccine efficacy. In patients with hematological (n = 182) and autoimmune diseases (n = 96), anti-SARS-CoV-2 and anti-PEG antibody titers were evaluated after a median of 33 days from 2nd vaccination. The median anti-SARS-CoV-2 antibody titers were 1901 AU/mL and 3832 AU/mL in patients with hematological and autoimmune disease, respectively. Multiple regression analysis showed that age and days from 2nd vaccination were negatively associated with anti-SARS-CoV-2 antibody titers. Anti-CD20 antibody treatment was negatively correlated with anti-SARS-CoV-2 antibody titers in hematological disease, and C-reactive protein (CRP) was positively correlated with anti-SARS-CoV-2 antibody titers in autoimmune disease. Baseline anti-PEG antibody titers were significantly higher in patients with autoimmune disease but were not correlated with anti-SARS-CoV-2 antibody titers. Patients with increased anti-PEG IgG acquired higher anti-SARS-CoV-2 antibody titers in patients with autoimmune disease. Anti-SARS-CoV-2 antibody acquisition was suboptimal in patients with hematological disease, but both anti-SARS-CoV-2 antibody and anti-PEG IgG were acquired in patients with autoimmune disease, reflecting robust humoral immune response. Pre-existing anti-PEG antibody titers did not affect anti-SARS-CoV-2 antibody acquisition.","ja":"The effects of vaccination are modified by hematological and autoimmune diseases and/or treatment. Anti-SARS-CoV-2 mRNA vaccine contains polyethylene glycol (PEG), it is largely unknown whether PEG influences the effects of vaccination or induces a humoral response. This study examined whether anti-PEG antibodies before vaccination (pre-existing) influenced the acquisition of SARS-CoV-2 antibodies and evaluated the relationship between the development of anti-SARS-CoV-2 antibodies and anti-PEG antibodies after SARS-CoV-2 vaccination in hematological and autoimmune diseases. Anti-SARS-CoV-2 antibody IgG, anti-PEG IgG, and IgM titers were evaluated in patients with hematological and autoimmune diseases after the second dose of BNT162B2. Anti-PEG IgG and IgM titers were also measured before vaccination to examine changes after vaccination and the relationship with vaccine efficacy. In patients with hematological (n = 182) and autoimmune diseases (n = 96), anti-SARS-CoV-2 and anti-PEG antibody titers were evaluated after a median of 33 days from 2nd vaccination. The median anti-SARS-CoV-2 antibody titers were 1901 AU/mL and 3832 AU/mL in patients with hematological and autoimmune disease, respectively. Multiple regression analysis showed that age and days from 2nd vaccination were negatively associated with anti-SARS-CoV-2 antibody titers. Anti-CD20 antibody treatment was negatively correlated with anti-SARS-CoV-2 antibody titers in hematological disease, and C-reactive protein (CRP) was positively correlated with anti-SARS-CoV-2 antibody titers in autoimmune disease. Baseline anti-PEG antibody titers were significantly higher in patients with autoimmune disease but were not correlated with anti-SARS-CoV-2 antibody titers. Patients with increased anti-PEG IgG acquired higher anti-SARS-CoV-2 antibody titers in patients with autoimmune disease. Anti-SARS-CoV-2 antibody acquisition was suboptimal in patients with hematological disease, but both anti-SARS-CoV-2 antibody and anti-PEG IgG were acquired in patients with autoimmune disease, reflecting robust humoral immune response. Pre-existing anti-PEG antibody titers did not affect anti-SARS-CoV-2 antibody acquisition."},"publication_date":"2024-05-17","publication_name":{"en":"Heliyon","ja":"Heliyon"},"volume":"10","number":"10","starting_page":"e31489","ending_page":"e31489","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.heliyon.2024.e31489"],"issn":["2405-8440"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:4, {"insert":{"user_id":"B000341201","type":"published_papers","id":"47364776"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2012308","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38614255","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=412142","label":"url"}],"paper_title":{"en":"Tl uptake and retention mimicking malignant lymphoma in a patient with human immunodeficiency virus infection.","ja":"Tl uptake and retention mimicking malignant lymphoma in a patient with human immunodeficiency virus infection."},"authors":{"en":[{"name":"Nakamura Shingen"},{"name":"Hara Keijiro"},{"name":"Kobayashi Tomoko"},{"name":"Sumitani Ryohei"},{"name":"Oura Masahiro"},{"name":"Maeda Yusaku"},{"name":"Sogabe Kimiko"},{"name":"Yagi Hikaru"},{"name":"Takahashi Mamiko"},{"name":"Fujii Shiroh"},{"name":"Harada Takeshi"},{"name":"Bando Yoshimi"},{"name":"Abe Masahiro"},{"name":"Miki Hirokazu"}],"ja":[{"name":"中村 信元"},{"name":"原 慶次郎"},{"name":"小林 智子"},{"name":"住谷 龍平"},{"name":"大浦 雅博"},{"name":"Maeda Yusaku"},{"name":"曽我部 公子"},{"name":"Yagi Hikaru"},{"name":"Takahashi Mamiko"},{"name":"藤井 志朗"},{"name":"原田 武志"},{"name":"坂東 良美"},{"name":"安倍 正博"},{"name":"三木 浩和"}]},"description":{"en":"Various opportunistic infections develop during immunodeficiency due to human immunodeficiency virus (HIV) infection. The treatment options for malignant lymphoma (ML) and toxoplasmic encephalitis (TE) are completely different; therefore, their discrimination is critical. A 25-year-old female of foreign nationality had been experiencing headaches for several weeks and suddenly developed convulsions. Brain computed tomography revealed multiple intracranial lesions; therefore, the patient was referred to the neurosurgery department. Brain magnetic resonance imaging (MRI) revealed multiple masses with surrounding edema, accompanied by enhanced contrast. The largest mass (2 cm) in the left occipital lobe exhibited ringed contrast enhancement. Her blood test results showed a CD4 count of 40/μL, positive HIV Ag/Ab, HIV-RNA level of 56 × 10 copies/mL, positive anti-Toxoplasma IgG (63 IU/mL), and negative anti-Toxoplasma IgM. Tl- single photon emission computed tomography (Tl-SPECT) revealed abnormal accumulation only in the tumor in the left occipital lobe (early T/N ratio, 3.034; delayed T/N ratio, 2.738; retention index, 0.9), which was suspected to be a ML. Both tumors, with or without high accumulation of Tl, were subjected to craniotomy biopsy. Pathological examination revealed infiltration of small lymphocytes with a necrotic background. The patient was diagnosed with TE based on a positive result of a tissue polymerase chain reaction test for Toxoplasma gondii. Two weeks after sulfamethoxazole and trimethoprim combination therapy, MRI imaging showed dramatic improvement in multiple brain tumors. This case is atypical because ML was ruled out despite high Tl-SPECT uptake and retention. Careful diagnosis through pathological examination and DNA testing is important.","ja":"Various opportunistic infections develop during immunodeficiency due to human immunodeficiency virus (HIV) infection. The treatment options for malignant lymphoma (ML) and toxoplasmic encephalitis (TE) are completely different; therefore, their discrimination is critical. A 25-year-old female of foreign nationality had been experiencing headaches for several weeks and suddenly developed convulsions. Brain computed tomography revealed multiple intracranial lesions; therefore, the patient was referred to the neurosurgery department. Brain magnetic resonance imaging (MRI) revealed multiple masses with surrounding edema, accompanied by enhanced contrast. The largest mass (2 cm) in the left occipital lobe exhibited ringed contrast enhancement. Her blood test results showed a CD4 count of 40/μL, positive HIV Ag/Ab, HIV-RNA level of 56 × 10 copies/mL, positive anti-Toxoplasma IgG (63 IU/mL), and negative anti-Toxoplasma IgM. Tl- single photon emission computed tomography (Tl-SPECT) revealed abnormal accumulation only in the tumor in the left occipital lobe (early T/N ratio, 3.034; delayed T/N ratio, 2.738; retention index, 0.9), which was suspected to be a ML. Both tumors, with or without high accumulation of Tl, were subjected to craniotomy biopsy. Pathological examination revealed infiltration of small lymphocytes with a necrotic background. The patient was diagnosed with TE based on a positive result of a tissue polymerase chain reaction test for Toxoplasma gondii. Two weeks after sulfamethoxazole and trimethoprim combination therapy, MRI imaging showed dramatic improvement in multiple brain tumors. This case is atypical because ML was ruled out despite high Tl-SPECT uptake and retention. Careful diagnosis through pathological examination and DNA testing is important."},"publication_date":"2024-04-12","publication_name":{"en":"Parasitology International","ja":"Parasitology International"},"volume":"101","starting_page":"102895","ending_page":"102895","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.parint.2024.102895"],"issn":["1873-0329"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:5, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38581458","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85189644856","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=418235","label":"url"}],"paper_title":{"en":"Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid","ja":"Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid"},"authors":{"en":[{"name":"Inoue Yusuke"},{"name":"Oda Asuka"},{"name":"Maeda Yusaku"},{"name":"Sumitani Ryohei"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Maruhashi Tomoko"},{"name":"Takahashi Mamiko"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Hiasa Masahiro"},{"name":"Teramachi Jumpei"},{"name":"Harada Takeshi"},{"name":"Abe Masahiro"}],"ja":[{"name":"Inoue Yusuke"},{"name":"Oda Asuka"},{"name":"前田 悠作"},{"name":"住谷 龍平"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"Maruhashi Tomoko"},{"name":"Takahashi Mamiko"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"日浅 雅博"},{"name":"寺町 順平"},{"name":"原田 武志"},{"name":"安倍 正博"}]},"description":{"en":"As multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2+ γδ T) cells serve as the first line of defense against pathogens as well as tumors and can be expanded ex vivo from peripheral blood mononuclear cells (PBMCs) upon treatment with amino-bisphosphonates in combination with IL-2. Here, we demonstrated that next-generation immunomodulators called cereblon E3 ligase modulators (CELMoDs), as well as lenalidomide and pomalidomide, expanded Th1-like Vδ2+ γδ T cells from PBMCs in the presence of zoledronic acid (ZA). However, the expansion of Th1-like Vδ2+ γδ T cells by these immunomodulatory drugs was abolished under IL-2 blockade, although IL-2 production was induced in PBMCs. BTN3A1 triggers phosphoantigen presentation to γδ T-cell receptors and is required for γδ T-cell expansion and activation. ZA but not these immunomodulatory drugs upregulated BTN3A1 in monocytes. These results suggest that immunomodulatory drugs and ZA have cooperative roles in expansion of Th1-like Vδ2+ γδ T cells, and provide the important knowledge for clinical application of human Vδ2+ γδ T cells as effector cells.","ja":"As multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2+ γδ T) cells serve as the first line of defense against pathogens as well as tumors and can be expanded ex vivo from peripheral blood mononuclear cells (PBMCs) upon treatment with amino-bisphosphonates in combination with IL-2. Here, we demonstrated that next-generation immunomodulators called cereblon E3 ligase modulators (CELMoDs), as well as lenalidomide and pomalidomide, expanded Th1-like Vδ2+ γδ T cells from PBMCs in the presence of zoledronic acid (ZA). However, the expansion of Th1-like Vδ2+ γδ T cells by these immunomodulatory drugs was abolished under IL-2 blockade, although IL-2 production was induced in PBMCs. BTN3A1 triggers phosphoantigen presentation to γδ T-cell receptors and is required for γδ T-cell expansion and activation. ZA but not these immunomodulatory drugs upregulated BTN3A1 in monocytes. These results suggest that immunomodulatory drugs and ZA have cooperative roles in expansion of Th1-like Vδ2+ γδ T cells, and provide the important knowledge for clinical application of human Vδ2+ γδ T cells as effector cells."},"publication_date":"2024-04-06","publication_name":{"en":"International Journal of Hematology","ja":"International Journal of Hematology"},"volume":"119","number":"6","starting_page":"626","ending_page":"630","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12185-024-03763-7"],"issn":["0925-5710"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:6, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=447551","label":"url"}],"paper_title":{"en":"Phase Angle and Extracellular Water-to-Total Body Water Ratio Measured by Bioelectrical Impedance Analysis","ja":"Phase Angle and Extracellular Water-to-Total Body Water Ratio Measured by Bioelectrical Impedance Analysis"},"authors":{"en":[{"name":"Hori Taiki"},{"name":"Nakamura Shingen"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"堀 太貴"},{"name":"中村 信元"},{"name":"粟飯原 賢一"}]},"publication_date":"2024","publication_name":{"en":"J Leuk. 12:368,2024.","ja":"J Leuk. 12:368,2024."},"languages":["eng"],"referee":true,"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:7, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37601887","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=408113","label":"url"}],"paper_title":{"en":"Therapeutic efficacy of the resorcylic acid lactone LL-Z1640-2 for adult T-cell leukaemia/lymphoma","ja":"Therapeutic efficacy of the resorcylic acid lactone LL-Z1640-2 for adult T-cell leukaemia/lymphoma"},"authors":{"en":[{"name":"Oura Masahiro"},{"name":"Harada Takeshi"},{"name":"Oda Asuka"},{"name":"Teramachi Jumpei"},{"name":"Nakayama Atsushi"},{"name":"Sumitani Ryohei"},{"name":"Inoue Yusuke"},{"name":"Maeda Yusaku"},{"name":"Sogabe Kimiko"},{"name":"Tomoko Maruhashi"},{"name":"Takahashi Mamiko"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Nakamura Shingen"},{"name":"Hara Tomoyo"},{"name":"Yamagami Hiroki"},{"name":"Kurahashi Kiyoe"},{"name":"Endo Itsuro"},{"name":"Hasegawa Hiroo"},{"name":"Fujiwara Hiroshi"},{"name":"Abe Masahiro"}],"ja":[{"name":"大浦 雅博"},{"name":"原田 武志"},{"name":"小田 明日香"},{"name":"寺町 順平"},{"name":"中山 淳"},{"name":"住谷 龍平"},{"name":"井上 雄介"},{"name":"前田 悠作"},{"name":"曽我部 公子"},{"name":"丸橋 朋子"},{"name":"髙橋 真美子"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"中村 昌史"},{"name":"原 倫世"},{"name":"山上 紘規"},{"name":"倉橋 清衛"},{"name":"遠藤 逸朗"},{"name":"長谷川 寛雄"},{"name":"藤原 弘"},{"name":"安倍 正博"}]},"description":{"en":"Adult T-cell leukaemia/lymphoma (ATL) remains incurable. The NF-κB and interferon regulatory factor 4 (IRF4) signalling pathways are among the critical survival pathways for the progression of ATL. TGF-β-activated kinase 1 (TAK1), an IκB kinase-activating kinase, triggers the activation of NF-κB. The resorcylic acid lactone LL-Z1640-2 is a potent irreversible inhibitor of TAK1/extracellular signal-regulated kinase 2 (ERK2). We herein examined the therapeutic efficacy of LL-Z1640-2 against ATL. LL-Z1640-2 effectively suppressed the in vivo growth of ATL cells. It induced in vitro apoptosis and inhibited the nuclear translocation of p65/RelA in ATL cells. The knockdown of strongly induced ATL cell death while downregulating MYC. LL-Z1640-2 as well as the NF-κB inhibitor BAY11-7082 decreased the expression of IRF4 and MYC at the protein and mRNA levels, indicating the suppression of the NF-κB-IRF4-MYC axis. The treatment with LL-Z1640-2 also mitigated the phosphorylation of p38 MAPK along with the expression of CC chemokine receptor 4. Furthermore, the inhibition of STAT3/5 potentiated the cytotoxic activity of LL-Z1640-2 against IL-2-responsive ATL cells in the presence of IL-2. Therefore, LL-Z1640-2 appears to be an effective treatment for ATL. Further studies are needed to develop more potent compounds that retain the active motifs of LL-Z1640-2.","ja":"Adult T-cell leukaemia/lymphoma (ATL) remains incurable. The NF-κB and interferon regulatory factor 4 (IRF4) signalling pathways are among the critical survival pathways for the progression of ATL. TGF-β-activated kinase 1 (TAK1), an IκB kinase-activating kinase, triggers the activation of NF-κB. The resorcylic acid lactone LL-Z1640-2 is a potent irreversible inhibitor of TAK1/extracellular signal-regulated kinase 2 (ERK2). We herein examined the therapeutic efficacy of LL-Z1640-2 against ATL. LL-Z1640-2 effectively suppressed the in vivo growth of ATL cells. It induced in vitro apoptosis and inhibited the nuclear translocation of p65/RelA in ATL cells. The knockdown of strongly induced ATL cell death while downregulating MYC. LL-Z1640-2 as well as the NF-κB inhibitor BAY11-7082 decreased the expression of IRF4 and MYC at the protein and mRNA levels, indicating the suppression of the NF-κB-IRF4-MYC axis. The treatment with LL-Z1640-2 also mitigated the phosphorylation of p38 MAPK along with the expression of CC chemokine receptor 4. Furthermore, the inhibition of STAT3/5 potentiated the cytotoxic activity of LL-Z1640-2 against IL-2-responsive ATL cells in the presence of IL-2. Therefore, LL-Z1640-2 appears to be an effective treatment for ATL. Further studies are needed to develop more potent compounds that retain the active motifs of LL-Z1640-2."},"publication_date":"2023-07-27","publication_name":{"en":"eJHaem","ja":"eJHaem"},"volume":"4","number":"3","starting_page":"667","ending_page":"678","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/jha2.758"],"issn":["2688-6146"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:8, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2010981","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36129197","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=396173","label":"url"}],"paper_title":{"en":"Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase","ja":"Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase"},"authors":{"en":[{"name":"Harada Takeshi"},{"name":"Ohguchi Hiroto"},{"name":"Oda Asuka"},{"name":"Nakao Michiyasu"},{"name":"Teramachi Jumpei"},{"name":"Hiasa Masahiro"},{"name":"Sumitani Ryohei"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Maruhashi Tomoko"},{"name":"Takahashi Mamiko"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Ozaki Shuji"},{"name":"Sano Shigeki"},{"name":"Hideshima Teru"},{"name":"Abe Masahiro"}],"ja":[{"name":"原田 武志"},{"name":"大口 裕人"},{"name":"小田 明日香"},{"name":"中尾 允泰"},{"name":"寺町 順平"},{"name":"日浅 雅博"},{"name":"住谷 龍平"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"丸橋 朋子"},{"name":"高橋 真美子"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"尾崎 修治"},{"name":"佐野 茂樹"},{"name":"秀島 輝"},{"name":"安倍 正博"}]},"description":{"en":"Multiple myeloma (MM) preferentially expands and acquires drug resistance in the bone marrow (BM). We herein examined the role of histone deacetylase 1 (HDAC1) in the constitutive activation of the master transcription factor IRF4 and the prosurvival mediator PIM2 kinase in MM cells. The knockdown or inhibition of HDAC1 by the class I HDAC inhibitor MS-275 reduced the basal expression of IRF4 and PIM2 in MM cells. Mechanistically, the inhibition of HDAC1 decreased IRF4 transcription through histone hyperacetylation and inhibiting the recruitment of RNA polymerase II at the IRF4 locus, thereby reducing IRF4-targeting genes, including PIM2. In addition to the transcriptional regulation of PIM2 by the HDAC1-IRF4 axis, PIM2 was markedly upregulated by external stimuli from BM stromal cells and interleukin-6 (IL-6). Upregulated PIM2 contributed to the attenuation of the cytotoxic effects of MS-275. Class I HDAC and PIM kinase inhibitors cooperatively suppressed MM cell growth in the presence of IL-6 and in vivo. Therefore, the present results demonstrate the potential of the simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 as an efficient therapeutic option for MM fostered in the BM.","ja":"Multiple myeloma (MM) preferentially expands and acquires drug resistance in the bone marrow (BM). We herein examined the role of histone deacetylase 1 (HDAC1) in the constitutive activation of the master transcription factor IRF4 and the prosurvival mediator PIM2 kinase in MM cells. The knockdown or inhibition of HDAC1 by the class I HDAC inhibitor MS-275 reduced the basal expression of IRF4 and PIM2 in MM cells. Mechanistically, the inhibition of HDAC1 decreased IRF4 transcription through histone hyperacetylation and inhibiting the recruitment of RNA polymerase II at the IRF4 locus, thereby reducing IRF4-targeting genes, including PIM2. In addition to the transcriptional regulation of PIM2 by the HDAC1-IRF4 axis, PIM2 was markedly upregulated by external stimuli from BM stromal cells and interleukin-6 (IL-6). Upregulated PIM2 contributed to the attenuation of the cytotoxic effects of MS-275. Class I HDAC and PIM kinase inhibitors cooperatively suppressed MM cell growth in the presence of IL-6 and in vivo. Therefore, the present results demonstrate the potential of the simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 as an efficient therapeutic option for MM fostered in the BM."},"publication_date":"2023-03-28","publication_name":{"en":"Blood Advances","ja":"Blood Advances"},"volume":"7","number":"6","starting_page":"1019","ending_page":"1032","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1182/bloodadvances.2022007155"],"issn":["2473-9537"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:9, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36708147","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85147389240","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393449","label":"url"}],"paper_title":{"en":"Clinical impact of anti-polyethylene glycol (PEG) antibody in haematological patients administered PEGylated-granulocyte colony-stimulating factor","ja":"Clinical impact of anti-polyethylene glycol (PEG) antibody in haematological patients administered PEGylated-granulocyte colony-stimulating factor"},"authors":{"en":[{"name":"Okada Naoto"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Nakamura Shingen"},{"name":"Goda Mitsuhiro"},{"name":"Abe Masahiro"},{"name":"Kitahara Takashi"},{"name":"Ishida Tatsuhiro"},{"name":"Ishizawa Keisuke"}],"ja":[{"name":"Okada Naoto"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"中村 信元"},{"name":"Goda Mitsuhiro"},{"name":"Abe Masahiro"},{"name":"Kitahara Takashi"},{"name":"石田 竜弘"},{"name":"Ishizawa Keisuke"}]},"description":{"en":"Polyethylene glycol (PEG) is a polymer covalently attached to proteins to improve their half-life and efficacy. We previously reported that the PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) is immunogenic, which could adversely impact drug efficacy and safety in animal models. Here, we analyzed the relationship between anti-PEG antibody titers and the clinical impact of PEG-G-CSF in 19 hematological patients. A gradual decrease of anti-PEG antibody titers from baseline was observed after PEG-G-CSF administration. Of the 19 participants, 10 were assessed for noninfectious fever after the first administration of PEG-G-CSF and three experienced this reaction. The receiver operating characteristic curve revealed that the cut-off values of pretreated anti-PEG IgM and IgG titers for noninfectious fever were set at 5.0 and 96.6 U/mL, respectively. All patients who experienced noninfectious fever had anti-PEG antibody titers above this cut-off value (P = .033). An enzyme-linked immunosorbent assay revealed that some anti-PEG antibodies in patients with anti-PEG antibody titers above the cut-off value reacted with the PEGylated liposome. These results indicate the reactivity of the anti-PEG antibodies to PEGylated therapeutics observed in hematologic patients and the possibility of the relationship between high titers of anti-PEG antibodies and the development of adverse events after PEG-G-CSF administration.","ja":"Polyethylene glycol (PEG) is a polymer covalently attached to proteins to improve their half-life and efficacy. We previously reported that the PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) is immunogenic, which could adversely impact drug efficacy and safety in animal models. Here, we analyzed the relationship between anti-PEG antibody titers and the clinical impact of PEG-G-CSF in 19 hematological patients. A gradual decrease of anti-PEG antibody titers from baseline was observed after PEG-G-CSF administration. Of the 19 participants, 10 were assessed for noninfectious fever after the first administration of PEG-G-CSF and three experienced this reaction. The receiver operating characteristic curve revealed that the cut-off values of pretreated anti-PEG IgM and IgG titers for noninfectious fever were set at 5.0 and 96.6 U/mL, respectively. All patients who experienced noninfectious fever had anti-PEG antibody titers above this cut-off value (P = .033). An enzyme-linked immunosorbent assay revealed that some anti-PEG antibodies in patients with anti-PEG antibody titers above the cut-off value reacted with the PEGylated liposome. These results indicate the reactivity of the anti-PEG antibodies to PEGylated therapeutics observed in hematologic patients and the possibility of the relationship between high titers of anti-PEG antibodies and the development of adverse events after PEG-G-CSF administration."},"publication_date":"2023-01-28","publication_name":{"en":"Clinical Pharmacology in Drug Development","ja":"Clinical Pharmacology in Drug Development"},"volume":"12","number":"8","starting_page":"826","ending_page":"831","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/cpdd.1225"],"issn":["2160-7648"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:10, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35811059","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388295","label":"url"}],"paper_title":{"en":"First reported case of Lachnoanaerobaculum gingivalis bacteremia in an acute myeloid leukemia patient with oral mucositis during high dose chemotherapy.","ja":"First reported case of Lachnoanaerobaculum gingivalis bacteremia in an acute myeloid leukemia patient with oral mucositis during high dose chemotherapy."},"authors":{"en":[{"name":"Okada Naoto"},{"name":"Murakami Akikazu"},{"name":"Satou Masami"},{"name":"Nakamura Shingen"},{"name":"Fujii Shiroh"},{"name":"Sogabe Kimiko"},{"name":"Takahashi Mamiko"},{"name":"Okada Asami"},{"name":"Abe Akane"},{"name":"Fujii Hideki"},{"name":"Abe Masahiro"},{"name":"Azuma Momoyo"},{"name":"Ishizawa Keisuke"}],"ja":[{"name":"岡田 直人"},{"name":"村上 明一"},{"name":"Satou Masami"},{"name":"中村 信元"},{"name":"藤井 志朗"},{"name":"曽我部 公子"},{"name":"Takahashi Mamiko"},{"name":"Okada Asami"},{"name":"阿部 あかね"},{"name":"藤猪 英樹"},{"name":"安倍 正博"},{"name":"東 桃代"},{"name":"石澤 啓介"}]},"description":{"en":"During chemotherapy in patients with oral mucositis, we should consider the possibility of L. gingivalis bacteremia.","ja":"During chemotherapy in patients with oral mucositis, we should consider the possibility of L. gingivalis bacteremia."},"publication_date":"2022-07-08","publication_name":{"en":"Anaerobe","ja":"Anaerobe"},"volume":"76","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.anaerobe.2022.102610"],"issn":["1095-8274"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:11, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35534187","label":"url"},{"@id":"https://www.scopus.com/pages/publications/105004563696","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=394086","label":"url"}],"paper_title":{"en":"Allogeneic haematopoietic stem cell transplantation and patient falls: impact of lower extremity muscle strength.","ja":"Allogeneic haematopoietic stem cell transplantation and patient falls: impact of lower extremity muscle strength."},"authors":{"en":[{"name":"Kondo Shin"},{"name":"Inoue Tatsuro"},{"name":"Saito Takashi"},{"name":"Kawamura Yuka"},{"name":"Katayama Ayane"},{"name":"Nakamura Masafumi"},{"name":"Sumitani Ryohei"},{"name":"Takahashi Mamiko"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Sato Nori"},{"name":"Ono Rei"},{"name":"Abe Masahiro"},{"name":"Katoh Shinsuke"}],"ja":[{"name":"Kondo Shin"},{"name":"Inoue Tatsuro"},{"name":"Saito Takashi"},{"name":"Kawamura Yuka"},{"name":"Katayama Ayane"},{"name":"Nakamura Masafumi"},{"name":"住谷 龍平"},{"name":"Takahashi Mamiko"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"佐藤 紀"},{"name":"Ono Rei"},{"name":"安倍 正博"},{"name":"加藤 真介"}]},"description":{"en":"Patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) have a higher risk of falls than those receiving other therapies for haematological disorders. This study aimed to investigate the impact of pretransplant lower extremity muscle strength (LEMS) on post-transplant falls. In this retrospective cohort study, patients aged ≥18 years who underwent allo-HSCT were included. All data were extracted from medical records. LEMS was defined as the knee extension force measured by a handheld dynamometer divided by the patient's weight. The receiver operating characteristic (ROC) curve was used to calculate the optimal LEMS cut-off value for prediction of falls. Patients were categorised into low and normal LEMS groups based on the cut-off value. The impact of pretransplant LEMS on post-transplant falls was analysed using a Cox proportional hazards model. In total, 101 patients were analysed. During the observation period, falls occurred in 32 patients (31.7%). The ROC curve analysis results showed that the optimal LEMS cut-off value for prediction of falls was 45.4% per body weight. In multivariate analysis, pretransplant low LEMS was a significant predictor of falls in model 1 with patient characteristics as a confounding factor and model 2 with medications-inducing falls as a confounding factor, respectively (model 1: HR 3.23, 95% CI 1.37 to 7.64; model 2: HR 2.82, 95% CI 1.20 to 6.59). Pretransplant LEMS was a significant predictor of post-transplant falls. The results of this study may help to prevent falls in patients undergoing allo-HSCT.","ja":"Patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) have a higher risk of falls than those receiving other therapies for haematological disorders. This study aimed to investigate the impact of pretransplant lower extremity muscle strength (LEMS) on post-transplant falls. In this retrospective cohort study, patients aged ≥18 years who underwent allo-HSCT were included. All data were extracted from medical records. LEMS was defined as the knee extension force measured by a handheld dynamometer divided by the patient's weight. The receiver operating characteristic (ROC) curve was used to calculate the optimal LEMS cut-off value for prediction of falls. Patients were categorised into low and normal LEMS groups based on the cut-off value. The impact of pretransplant LEMS on post-transplant falls was analysed using a Cox proportional hazards model. In total, 101 patients were analysed. During the observation period, falls occurred in 32 patients (31.7%). The ROC curve analysis results showed that the optimal LEMS cut-off value for prediction of falls was 45.4% per body weight. In multivariate analysis, pretransplant low LEMS was a significant predictor of falls in model 1 with patient characteristics as a confounding factor and model 2 with medications-inducing falls as a confounding factor, respectively (model 1: HR 3.23, 95% CI 1.37 to 7.64; model 2: HR 2.82, 95% CI 1.20 to 6.59). Pretransplant LEMS was a significant predictor of post-transplant falls. The results of this study may help to prevent falls in patients undergoing allo-HSCT."},"publication_date":"2022-05-09","publication_name":{"en":"BMJ Supportive & Palliative Care","ja":"BMJ Supportive & Palliative Care"},"volume":"15","number":"3","starting_page":"379","ending_page":"386","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/bmjspcare-2022-003582"],"issn":["2045-4368"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:12, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34949601","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=394089","label":"url"}],"paper_title":{"en":"Allogeneic haematopoietic stem cell transplantation-clinical outcomes: impact of leg muscle strength.","ja":"Allogeneic haematopoietic stem cell transplantation-clinical outcomes: impact of leg muscle strength."},"authors":{"en":[{"name":"Kondo Shin"},{"name":"Kagawa Kumiko"},{"name":"Saito Takashi"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Sato Nori"},{"name":"Ono Rei"},{"name":"Abe Masahiro"},{"name":"Katoh Shinsuke"}],"ja":[{"name":"Kondo Shin"},{"name":"Kagawa Kumiko"},{"name":"Saito Takashi"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"佐藤 紀"},{"name":"Ono Rei"},{"name":"安倍 正博"},{"name":"加藤 真介"}]},"description":{"en":"Pre-transplant LEMS was a significant factor in predicting OS and NRM.","ja":"Pre-transplant LEMS was a significant factor in predicting OS and NRM."},"publication_date":"2021-12-23","publication_name":{"en":"BMJ Supportive & Palliative Care","ja":"BMJ Supportive & Palliative Care"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/bmjspcare-2021-003256"],"issn":["2045-4368"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:13, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2011123","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34585530","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85115829007","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388299","label":"url"}],"paper_title":{"en":"Artifactual prolongation of the activated partial thromboplastin time by amikacin or gentamicin with ellagic acid, but not silica activated reagent.","ja":"Artifactual prolongation of the activated partial thromboplastin time by amikacin or gentamicin with ellagic acid, but not silica activated reagent."},"authors":{"en":[{"name":"Kaneko Yousuke"},{"name":"Sugasaki Motoki"},{"name":"Okada Naoto"},{"name":"Niimi Mako"},{"name":"Yasui Saya"},{"name":"Hori Taiki"},{"name":"Aihara Ken-ichi"},{"name":"Takishita Makoto"},{"name":"Abe Masahiro"},{"name":"Nakamura Shingen"}],"ja":[{"name":"Kaneko Yousuke"},{"name":"Sugasaki Motoki"},{"name":"岡田 直人"},{"name":"Niimi Mako"},{"name":"安井 沙耶"},{"name":"堀 太貴"},{"name":"粟飯原 賢一"},{"name":"Takishita Makoto"},{"name":"安倍 正博"},{"name":"中村 信元"}]},"publication_date":"2021-09-29","publication_name":{"en":"International Journal of Laboratory Hematology","ja":"International Journal of Laboratory Hematology"},"volume":"44","number":"2","starting_page":"e72","ending_page":"e75","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/ijlh.13718"],"issn":["1751-553X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:14, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2009431","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32273474","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=377110","label":"url"}],"paper_title":{"en":"TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma","ja":"TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma"},"authors":{"en":[{"name":"Teramachi Jumpei"},{"name":"Tenshin Hirofumi"},{"name":"Hiasa Masahiro"},{"name":"Oda Asuka"},{"name":"Bat-Erdene Ariunzaya"},{"name":"Harada Takeshi"},{"name":"Nakamura Shingen"},{"name":"Ashtar Mohannad"},{"name":"Shimizu Sou"},{"name":"Iwasa Masami"},{"name":"Sogabe Kimiko"},{"name":"Oura Masahiro"},{"name":"Fujii Shiroh"},{"name":"Kagawa Kumiko"},{"name":"Miki Hirokazu"},{"name":"Endo Itsuro"},{"name":"Haneji Tatsuji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"寺町 順平"},{"name":"天眞 寛文"},{"name":"日浅 雅博"},{"name":"小田 明日香"},{"name":"Ariunzaya Bat-Erdene"},{"name":"原田 武志"},{"name":"中村 信元"},{"name":"ASHTAR MOHANNAD"},{"name":"清水 宗"},{"name":"岩佐 昌美"},{"name":"曽我部 公子"},{"name":"大浦 雅博"},{"name":"藤井 志朗"},{"name":"賀川 久美子"},{"name":"三木 浩和"},{"name":"遠藤 逸朗"},{"name":"羽地 達次"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"Along with the tumor progression, the bone marrow microenvironment is skewed in multiple myeloma (MM), which underlies the unique pathophysiology of MM and confers aggressiveness and drug resistance in MM cells. TGF-β-activated kinase-1 (TAK1) mediates a wide range of intracellular signaling pathways. We demonstrate here that TAK1 is constitutively overexpressed and phosphorylated in MM cells, and that TAK1 inhibition suppresses the activation of NF-κB, p38MAPK, ERK and STAT3 to decrease the expression of critical mediators for MM growth and survival, including PIM2, MYC, Mcl-1, IRF4, and Sp1, along with a substantial reduction in the angiogenic factor VEGF in MM cells. Intriguingly, TAK1 phosphorylation was also induced along with upregulation of vascular cell adhesion molecule-1 (VCAM-1) in bone marrow stromal cells (BMSCs) in cocultures with MM cells, which facilitated MM cell-BMSC adhesion while inducing IL-6 production and receptor activator of nuclear factor κ-Β ligand (RANKL) expression by BMSCs. TAK1 inhibition effectively impaired MM cell adhesion to BMSCs to disrupt the support of MM cell growth and survival by BMSCs. Furthermore, TAK1 inhibition suppressed osteoclastogenesis enhanced by RANKL in cocultures of bone marrow cells with MM cells, and restored osteoblastic differentiation suppressed by MM cells or inhibitory factors for osteoblastogenesis overproduced in MM. Finally, treatment with the TAK1 inhibitor LLZ1640-2 markedly suppressed MM tumor growth and prevented bone destruction and loss in mouse MM models. Therefore, TAK1 inhibition may be a promising therapeutic option targeting not only MM cells but also the skewed bone marrow microenvironment in MM.","ja":"Along with the tumor progression, the bone marrow microenvironment is skewed in multiple myeloma (MM), which underlies the unique pathophysiology of MM and confers aggressiveness and drug resistance in MM cells. TGF-β-activated kinase-1 (TAK1) mediates a wide range of intracellular signaling pathways. We demonstrate here that TAK1 is constitutively overexpressed and phosphorylated in MM cells, and that TAK1 inhibition suppresses the activation of NF-κB, p38MAPK, ERK and STAT3 to decrease the expression of critical mediators for MM growth and survival, including PIM2, MYC, Mcl-1, IRF4, and Sp1, along with a substantial reduction in the angiogenic factor VEGF in MM cells. Intriguingly, TAK1 phosphorylation was also induced along with upregulation of vascular cell adhesion molecule-1 (VCAM-1) in bone marrow stromal cells (BMSCs) in cocultures with MM cells, which facilitated MM cell-BMSC adhesion while inducing IL-6 production and receptor activator of nuclear factor κ-Β ligand (RANKL) expression by BMSCs. TAK1 inhibition effectively impaired MM cell adhesion to BMSCs to disrupt the support of MM cell growth and survival by BMSCs. Furthermore, TAK1 inhibition suppressed osteoclastogenesis enhanced by RANKL in cocultures of bone marrow cells with MM cells, and restored osteoblastic differentiation suppressed by MM cells or inhibitory factors for osteoblastogenesis overproduced in MM. Finally, treatment with the TAK1 inhibitor LLZ1640-2 markedly suppressed MM tumor growth and prevented bone destruction and loss in mouse MM models. Therefore, TAK1 inhibition may be a promising therapeutic option targeting not only MM cells but also the skewed bone marrow microenvironment in MM."},"publication_date":"2021-05-01","publication_name":{"en":"Haematologica","ja":"Haematologica"},"volume":"106","number":"5","starting_page":"1401","ending_page":"1413","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3324/haematol.2019.234476"],"issn":["1592-8721"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:15, {"insert":{"user_id":"B000341201","type":"published_papers","id":"32804690"},"force":{"see_also":[{"@id":"http://search.jamas.or.jp/link/ui/2019335915","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=367930","label":"url"}],"paper_title":{"en":"芽球様の形態を示した肝脾型T細胞リンパ腫の一症例","ja":"芽球様の形態を示した肝脾型T細胞リンパ腫の一症例"},"authors":{"en":[{"name":"井上 雄介"},{"name":"Ikegame Akishige"},{"name":"徳永 尚樹"},{"name":"井上 千尋"},{"name":"Nakao Takayuki"},{"name":"Nagai Kojiro"},{"name":"高橋 真美子"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Abe Masahiro"}],"ja":[{"name":"井上 雄介"},{"name":"池亀 彰茂"},{"name":"徳永 尚樹"},{"name":"井上 千尋"},{"name":"中尾 隆之"},{"name":"長井 幸二郎"},{"name":"高橋 真美子"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"安倍 正博"}]},"description":{"en":"肝脾型T細胞性リンパ腫(HSTL)は肝および脾臓への浸潤を特徴とするT細胞性リンパ腫であり，全T細胞性リンパ腫の約3%を占める稀な腫瘍である．今回，末梢血および骨髄に異常細胞の出現を認め，急性白血病との鑑別が困難であったHSTLの一症例を経験した．症例は32歳女性，腹部膨満感および発熱のため近医を受診したところ，末梢血の異常細胞を指摘されたため，当院を受診した．臨床所見として著明な肝脾腫を認めたが，リンパ節腫脹は見られなかった．末梢血および骨髄中に出現した異常細胞の形態学的特徴からは急性白血病が疑われたが，細胞化学染色では酸性ホスファターゼ染色にのみ陽性を示した．フローサイトメトリー検査(FCM)ではT細胞系マーカーに陽性だが，CD5は陰性，CD8，CD16，CD56，CD11c，CD45RO，TCR-γδに陽性，CD4，CD10，CD25，CD34は陰性であった．免疫組織化学染色ではTIA-1陽性，GranzymeB陰性であり，非活性型細胞傷害性T細胞由来の細胞であることが推測され，以上の所見よりHSTLの白血化と診断した．HSTLは極めて予後不良であり，正確かつ迅速な診断が必要となるが，形態学的特徴からは急性白血病との鑑別が困難となることがある．正確な診断には形態学的所見に加えて臨床所見やFCM等の検査所見を併せて評価することが重要である．(著者抄録)","ja":"肝脾型T細胞性リンパ腫(HSTL)は肝および脾臓への浸潤を特徴とするT細胞性リンパ腫であり，全T細胞性リンパ腫の約3%を占める稀な腫瘍である．今回，末梢血および骨髄に異常細胞の出現を認め，急性白血病との鑑別が困難であったHSTLの一症例を経験した．症例は32歳女性，腹部膨満感および発熱のため近医を受診したところ，末梢血の異常細胞を指摘されたため，当院を受診した．臨床所見として著明な肝脾腫を認めたが，リンパ節腫脹は見られなかった．末梢血および骨髄中に出現した異常細胞の形態学的特徴からは急性白血病が疑われたが，細胞化学染色では酸性ホスファターゼ染色にのみ陽性を示した．フローサイトメトリー検査(FCM)ではT細胞系マーカーに陽性だが，CD5は陰性，CD8，CD16，CD56，CD11c，CD45RO，TCR-γδに陽性，CD4，CD10，CD25，CD34は陰性であった．免疫組織化学染色ではTIA-1陽性，GranzymeB陰性であり，非活性型細胞傷害性T細胞由来の細胞であることが推測され，以上の所見よりHSTLの白血化と診断した．HSTLは極めて予後不良であり，正確かつ迅速な診断が必要となるが，形態学的特徴からは急性白血病との鑑別が困難となることがある．正確な診断には形態学的所見に加えて臨床所見やFCM等の検査所見を併せて評価することが重要である．(著者抄録)"},"publication_date":"2019-07","publication_name":{"en":"Journal of the Japanese Society for Laboratory Hematology","ja":"日本検査血液学会雑誌"},"volume":"20","number":"2","starting_page":"231","ending_page":"237","languages":["jpn"],"referee":true,"identifiers":{"issn":["1347-2836"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:16, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2008741","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29277954","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85041047530","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345049","label":"url"}],"paper_title":{"en":"Cryptosporidiosis in a transplant recipient with severe intractable diarrhea: Detection of Cryptosporidium oocysts by intestinal biopsies.","ja":"Cryptosporidiosis in a transplant recipient with severe intractable diarrhea: Detection of Cryptosporidium oocysts by intestinal biopsies."},"authors":{"en":[{"name":"Kagawa Kumiko"},{"name":"Fujino Hikaru"},{"name":"Miki Hirokazu"},{"name":"Sogabe Kimiko"},{"name":"Takahashi Mamiko"},{"name":"Maruhashi Tomoko"},{"name":"Udaka Kengo"},{"name":"Iwasa Masami"},{"name":"Fujii Shiro"},{"name":"Nakamura Shingen"},{"name":"Abe Masahiro"}],"ja":[{"name":"賀川 久美子"},{"name":"藤野 ひかる"},{"name":"三木 浩和"},{"name":"曽我部 公子"},{"name":"髙橋 真美子"},{"name":"Maruhashi Tomoko"},{"name":"Udaka Kengo"},{"name":"Iwasa Masami"},{"name":"Fujii Shiro"},{"name":"中村 信元"},{"name":"安倍 正博"}]},"description":{"en":"Disseminated Cryptosporidium infection results in manifestations similar to those of graft-versus-host disease (GVHD), which hampers the detection of Cryptosporidium infection after allogeneic hematopoietic stem cell transplantation. Surveillance of oocysts on the surface of intestinal epithelial cells is needed for early and appropriate detection of Cryptosporidium infection in transplant recipients on immunosuppressants with severe intractable diarrhea. We present the first case of Cryptosporidium meleagridis infection in Japan after allogeneic cord blood transplantation.","ja":"Disseminated Cryptosporidium infection results in manifestations similar to those of graft-versus-host disease (GVHD), which hampers the detection of Cryptosporidium infection after allogeneic hematopoietic stem cell transplantation. Surveillance of oocysts on the surface of intestinal epithelial cells is needed for early and appropriate detection of Cryptosporidium infection in transplant recipients on immunosuppressants with severe intractable diarrhea. We present the first case of Cryptosporidium meleagridis infection in Japan after allogeneic cord blood transplantation."},"publication_date":"2018-04","publication_name":{"en":"Transplant Infectious Disease","ja":"Transplant Infectious Disease"},"volume":"20","number":"2","starting_page":"e12826","ending_page":"e12826","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/tid.12826"],"issn":["1399-3062"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:17, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.scopus.com/pages/publications/84887490978","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=429188","label":"url"}],"paper_title":{"en":"Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients","ja":"Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients"},"authors":{"en":[{"name":"Watanabe T."},{"name":"Mitsuhashi M."},{"name":"Sagawa M."},{"name":"Ri M."},{"name":"Suzuki K."},{"name":"Abe M."},{"name":"Ohmachi K."},{"name":"Nakagawa Y."},{"name":"Nakamura Shingen"},{"name":"Chosa M."},{"name":"Iida S."},{"name":"Kizaki M."}],"ja":[{"name":"Watanabe T."},{"name":"Mitsuhashi M."},{"name":"Sagawa M."},{"name":"Ri M."},{"name":"Suzuki K."},{"name":"Abe M."},{"name":"Ohmachi K."},{"name":"Nakagawa Y."},{"name":"中村 信元"},{"name":"Chosa M."},{"name":"Iida S."},{"name":"Kizaki M."}]},"publication_date":"2013-10-01","publication_name":{"en":"Blood Cancer Journal","ja":"Blood Cancer Journal"},"volume":"3","number":"10","referee":true,"identifiers":{"doi":["10.1038/bcj.2013.47"],"issn":["2044-5385"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:18, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23609417","label":"url"},{"@id":"https://www.scopus.com/pages/publications/84879151676","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=270148","label":"url"}],"paper_title":{"en":"Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.","ja":"Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma."},"authors":{"en":[{"name":"Harada Takeshi"},{"name":"Ozaki Shuji"},{"name":"Oda Asuka"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"原田 武志"},{"name":"尾崎 修治"},{"name":"Oda Asuka"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"Takeuchi Kyoko"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"Transient inflammatory reactions have been reported in a subpopulation of patients with multiple myeloma (MM) during lenalidomide (Len) plus dexamethasone (DEX) therapy. Here, we examined serum levels of Th1 (IL-2 and IFN-) and Th2 cytokines (IL-6 and TNF-) in nine refractory or relapsed MM patients treated with Len plus low-dose DEX. Six patients showed elevation of C-reactive protein (CRP) after the initiation of therapy. In these patients, IFN- and IL-6 were also elevated in two and three patients, respectively. The remaining three patients showed no appreciable changes in CRP or these cytokines. Furthermore, Len enhanced the production of both Th1 and Th2 cytokines in normal peripheral blood mononuclear cells and in patient bone marrow mononuclear cells containing primary myeloma cells and lymphocytes. These results suggest that the modulation of the Th1 and Th2 cytokine production by Len may contribute to transient inflammatory reaction in MM patients.","ja":"Transient inflammatory reactions have been reported in a subpopulation of patients with multiple myeloma (MM) during lenalidomide (Len) plus dexamethasone (DEX) therapy. Here, we examined serum levels of Th1 (IL-2 and IFN-) and Th2 cytokines (IL-6 and TNF-) in nine refractory or relapsed MM patients treated with Len plus low-dose DEX. Six patients showed elevation of C-reactive protein (CRP) after the initiation of therapy. In these patients, IFN- and IL-6 were also elevated in two and three patients, respectively. The remaining three patients showed no appreciable changes in CRP or these cytokines. Furthermore, Len enhanced the production of both Th1 and Th2 cytokines in normal peripheral blood mononuclear cells and in patient bone marrow mononuclear cells containing primary myeloma cells and lymphocytes. These results suggest that the modulation of the Th1 and Th2 cytokine production by Len may contribute to transient inflammatory reaction in MM patients."},"publication_date":"2013-04-23","publication_name":{"en":"International Journal of Hematology","ja":"International Journal of Hematology"},"volume":"97","number":"6","starting_page":"743","ending_page":"748","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12185-013-1321-0"],"issn":["1865-3774"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:19, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/22430632","label":"url"},{"@id":"https://www.scopus.com/pages/publications/84865860989","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=430294","label":"url"}],"paper_title":{"en":"Small molecule antibody targeting HLA class i inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors","ja":"Small molecule antibody targeting HLA class i inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors"},"authors":{"en":[{"name":"Ikegame Akishige"},{"name":"Ozaki Shuji"},{"name":"Tsuji Daisuke"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Nakano A."},{"name":"Kagawa Kumiko"},{"name":"Takeuchi K."},{"name":"Abe Masahiro"},{"name":"Watanabe Keiichiro"},{"name":"Hiasa Masahiro"},{"name":"Kimura N."},{"name":"Kikuchi Y."},{"name":"Sakamoto A."},{"name":"Habu K."},{"name":"Endo M."},{"name":"Itou Kouji"},{"name":"Yamada-Okabe H."},{"name":"Matsumoto Toshio"}],"ja":[{"name":"池亀 彰茂"},{"name":"尾崎 修治"},{"name":"辻 大輔"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"Nakano A."},{"name":"賀川 久美子"},{"name":"Takeuchi K."},{"name":"安倍 正博"},{"name":"渡邉 佳一郎"},{"name":"日浅 雅博"},{"name":"Kimura N."},{"name":"Kikuchi Y."},{"name":"Sakamoto A."},{"name":"Habu K."},{"name":"Endo M."},{"name":"伊藤 孝司"},{"name":"Yamada-Okabe H."},{"name":"松本 俊夫"}]},"description":{"en":"Cancer stem cells have been proposed to be responsible for tumorigenesis and recurrence in various neoplastic diseases, including multiple myeloma (MM). We have previously reported that MM cells specifically express HLA class I at high levels and that single-chain Fv diabody against this molecule markedly induces MM cell death. Here we investigated the effect of a new diabody (C3B3) on cancer stem cell-like side population (SP) cells. SP fraction of MM cells highly expressed ABCG2 and exhibited resistance to chemotherapeutic agents; however, C3B3 induced cytotoxicity in both SP cells and main population (MP) cells to a similar extent. Moreover, C3B3 suppressed colony formation and tumorigenesis of SP cells in vitro and in vivo. Crosslinking of HLA class I by C3B3 mediated disruption of lipid rafts and actin aggregation, which led to inhibition of gene expression of β-catenin and pluripotency-associated transcription factors such as Sox2, Oct3/4 and Nanog. Conversely, knockdown of Sox2 and Oct3/4 mRNA reduced the proportion of SP cells, suggesting that these factors are essential in maintenance of SP fraction in MM cells. Thus, our findings reveal that immunotherapeutic approach by engineered antibodies can overcome drug resistance, and provide a new basis for development of cancer stem cell-targeted therapy.","ja":"Cancer stem cells have been proposed to be responsible for tumorigenesis and recurrence in various neoplastic diseases, including multiple myeloma (MM). We have previously reported that MM cells specifically express HLA class I at high levels and that single-chain Fv diabody against this molecule markedly induces MM cell death. Here we investigated the effect of a new diabody (C3B3) on cancer stem cell-like side population (SP) cells. SP fraction of MM cells highly expressed ABCG2 and exhibited resistance to chemotherapeutic agents; however, C3B3 induced cytotoxicity in both SP cells and main population (MP) cells to a similar extent. Moreover, C3B3 suppressed colony formation and tumorigenesis of SP cells in vitro and in vivo. Crosslinking of HLA class I by C3B3 mediated disruption of lipid rafts and actin aggregation, which led to inhibition of gene expression of β-catenin and pluripotency-associated transcription factors such as Sox2, Oct3/4 and Nanog. Conversely, knockdown of Sox2 and Oct3/4 mRNA reduced the proportion of SP cells, suggesting that these factors are essential in maintenance of SP fraction in MM cells. Thus, our findings reveal that immunotherapeutic approach by engineered antibodies can overcome drug resistance, and provide a new basis for development of cancer stem cell-targeted therapy."},"publication_date":"2012-03-20","publication_name":{"en":"Leukemia","ja":"Leukemia"},"volume":"26","number":"9","starting_page":"2124","ending_page":"2134","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/leu.2012.78"],"issn":["0887-6924"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:20, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/22389670","label":"url"},{"@id":"https://www.scopus.com/pages/publications/84857602657","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=430154","label":"url"}],"paper_title":{"en":"Inhibition of tace activity enhances the susceptibility of myeloma cells to TRAIL","ja":"Inhibition of tace activity enhances the susceptibility of myeloma cells to TRAIL"},"authors":{"en":[{"name":"Kagawa Kumiko"},{"name":"Nakano Ayako"},{"name":"Miki Hirokazu"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"Takeuchi Kyoko"},{"name":"Nakamura Shingen"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Yata Kenichiro"},{"name":"Ozaki Shuji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"賀川 久美子"},{"name":"Nakano Ayako"},{"name":"三木 浩和"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"Takeuchi Kyoko"},{"name":"中村 信元"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"Yata Kenichiro"},{"name":"尾崎 修治"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"TNF-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) selectively induces apoptosis in various cancer cells including myeloma (MM) cells. However, the susceptibility of MM cells to TRAIL is largely low in most of MM cells by yet largely unknown mechanisms. Because TNF-α converting enzyme (TACE) can cleave some TNF receptor family members, in the present study we explored the roles of proteolytic modulation by TACE in TRAIL receptor expression and TRAIL-mediated cytotoxicity in MM cells. MM cells preferentially expressed death receptor 4 (DR4) but not DR5 on their surface along with TACE. Conditioned media from RPMI8226 and U266 cells contained a soluble form of DR4. The DR4 levels in these conditioned media were reduced by TACE inhibition by the TACE inhibitor TAPI-0 as well as TACE siRNA. Conversely, the TACE inhibition restored surface levels of DR4 but not DR5 in these cells without affecting DR4 mRNA levels. The TACE inhibition was able to restore cell surface DR4 expression in MM cells even in the presence of bone marrow stromal cells or osteoclasts, and enhanced the cytotoxic effects of recombinant TRAIL and an agonistic antibody against DR4 on MM cells. These results demonstrate that MM cells post-translationally down-modulate the cell surface expression of DR4 through ectodomain shedding by endogenous TACE, and that TACE inhibition is able to restore cell surface DR4 levels and the susceptibility of MM cells to TRAIL or an agonistic antibody against DR4. Thus, TACE may protect MM cells from TRAIL-mediated death through down-modulation of cell-surface DR4. It can be envisaged that TACE inhibition augments clinical efficacy of TRAIL-based immunotherapy against MM, which eventually becomes resistant to the present therapeutic modalities.","ja":"TNF-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) selectively induces apoptosis in various cancer cells including myeloma (MM) cells. However, the susceptibility of MM cells to TRAIL is largely low in most of MM cells by yet largely unknown mechanisms. Because TNF-α converting enzyme (TACE) can cleave some TNF receptor family members, in the present study we explored the roles of proteolytic modulation by TACE in TRAIL receptor expression and TRAIL-mediated cytotoxicity in MM cells. MM cells preferentially expressed death receptor 4 (DR4) but not DR5 on their surface along with TACE. Conditioned media from RPMI8226 and U266 cells contained a soluble form of DR4. The DR4 levels in these conditioned media were reduced by TACE inhibition by the TACE inhibitor TAPI-0 as well as TACE siRNA. Conversely, the TACE inhibition restored surface levels of DR4 but not DR5 in these cells without affecting DR4 mRNA levels. The TACE inhibition was able to restore cell surface DR4 expression in MM cells even in the presence of bone marrow stromal cells or osteoclasts, and enhanced the cytotoxic effects of recombinant TRAIL and an agonistic antibody against DR4 on MM cells. These results demonstrate that MM cells post-translationally down-modulate the cell surface expression of DR4 through ectodomain shedding by endogenous TACE, and that TACE inhibition is able to restore cell surface DR4 levels and the susceptibility of MM cells to TRAIL or an agonistic antibody against DR4. Thus, TACE may protect MM cells from TRAIL-mediated death through down-modulation of cell-surface DR4. It can be envisaged that TACE inhibition augments clinical efficacy of TRAIL-based immunotherapy against MM, which eventually becomes resistant to the present therapeutic modalities."},"publication_date":"2012-02-28","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"7","number":"2","starting_page":"e31594","ending_page":"e31594","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pone.0031594"],"issn":["1932-6203"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:21, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/22298254","label":"url"},{"@id":"https://www.scopus.com/pages/publications/84858706673","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=430149","label":"url"}],"paper_title":{"en":"Up-regulation of hexokinaseII in myeloma cells: Targeting myeloma cells with 3-bromopyruvate","ja":"Up-regulation of hexokinaseII in myeloma cells: Targeting myeloma cells with 3-bromopyruvate"},"authors":{"en":[{"name":"Nakano Ayako"},{"name":"Miki Hirokazu"},{"name":"Nakamura Shingen"},{"name":"Harada Takeshi"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"Fujii Shiroh"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Ozaki Shuji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"Nakano Ayako"},{"name":"三木 浩和"},{"name":"中村 信元"},{"name":"原田 武志"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"藤井 志朗"},{"name":"賀川 久美子"},{"name":"Takeuchi Kyoko"},{"name":"尾崎 修治"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"Hexokinase II (HKII), a key enzyme of glycolysis, is widely over-expressed in cancer cells. However, HKII levels and its roles in ATP production and ATP-dependent cellular process have not been well studied in hematopoietic malignant cells including multiple myeloma (MM) cells.We demonstrate herein that HKII is constitutively over-expressed in MM cells. 3-bromopyruvate (3BrPA), an inhibitor of HKII, promptly and substantially suppresses ATP production and induces cell death in MM cells. Interestingly, cocultures with osteoclasts (OCs) but not bone marrow stromal cells (BMSCs) enhanced the phosphorylation of Akt along with an increase in HKII levels and lactate production in MM cells. The enhancement of HKII levels and lactate production in MM cells by OCs were mostly abrogated by the PI3K inhibitor LY294002, suggesting activation of glycolysis in MM cells by OCs via the PI3K-Akt-HKII pathway. Although BMSCs and OCs stimulate MM cell growth and survival, 3BrPA induces cell death in MM cells even in cocultures with OCs as well as BMSCs. Furthermore, 3BrPA was able to diminish ATP-dependent ABC transporter activity to restore drug retention in MM cells in the presence of OCs. These results may underpin possible clinical application of 3BrPA in patients with MM.","ja":"Hexokinase II (HKII), a key enzyme of glycolysis, is widely over-expressed in cancer cells. However, HKII levels and its roles in ATP production and ATP-dependent cellular process have not been well studied in hematopoietic malignant cells including multiple myeloma (MM) cells.We demonstrate herein that HKII is constitutively over-expressed in MM cells. 3-bromopyruvate (3BrPA), an inhibitor of HKII, promptly and substantially suppresses ATP production and induces cell death in MM cells. Interestingly, cocultures with osteoclasts (OCs) but not bone marrow stromal cells (BMSCs) enhanced the phosphorylation of Akt along with an increase in HKII levels and lactate production in MM cells. The enhancement of HKII levels and lactate production in MM cells by OCs were mostly abrogated by the PI3K inhibitor LY294002, suggesting activation of glycolysis in MM cells by OCs via the PI3K-Akt-HKII pathway. Although BMSCs and OCs stimulate MM cell growth and survival, 3BrPA induces cell death in MM cells even in cocultures with OCs as well as BMSCs. Furthermore, 3BrPA was able to diminish ATP-dependent ABC transporter activity to restore drug retention in MM cells in the presence of OCs. These results may underpin possible clinical application of 3BrPA in patients with MM."},"publication_date":"2012-02","publication_name":{"en":"Journal of Bioenergetics and Biomembranes","ja":"Journal of Bioenergetics and Biomembranes"},"volume":"44","number":"1","starting_page":"31","ending_page":"38","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10863-012-9412-9"],"issn":["0145-479X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:22, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2000213","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/22073292","label":"url"},{"@id":"https://www.scopus.com/pages/publications/80355146252","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=252725","label":"url"}],"paper_title":{"en":"Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells.","ja":"Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells."},"authors":{"en":[{"name":"Nakano Ayako"},{"name":"Tsuji Daisuke"},{"name":"Miki Hirokazu"},{"name":"Cui Qu"},{"name":"El Sayed Salah Mohamed"},{"name":"Ikegame Akishige"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"Nakamura Shingen"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Sakai Akira"},{"name":"Ozaki Shuji"},{"name":"Okano Kazuma"},{"name":"Nakamura Takahiro"},{"name":"Itou Kouji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"Nakano Ayako"},{"name":"辻 大輔"},{"name":"三木 浩和"},{"name":"Cui Qu"},{"name":"El Sayed Salah Mohamed"},{"name":"Ikegame Akishige"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"中村 信元"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"賀川 久美子"},{"name":"Takeuchi Kyoko"},{"name":"Sakai Akira"},{"name":"尾崎 修治"},{"name":"Okano Kazuma"},{"name":"Nakamura Takahiro"},{"name":"伊藤 孝司"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"Cancer cells eventually acquire drug resistance largely via the aberrant expression of ATP-binding cassette (ABC) transporters, ATP-dependent efflux pumps. Because cancer cells produce ATP mostly through glycolysis, in the present study we explored the effects of inhibiting glycolysis on the ABC transporter function and drug sensitivity of malignant cells. Inhibition of glycolysis by 3-bromopyruvate (3BrPA) suppressed ATP production in malignant cells, and restored the retention of daunorubicin or mitoxantrone in ABC transporter-expressing, RPMI8226 (ABCG2), KG-1 (ABCB1) and HepG2 cells (ABCB1 and ABCG2). Interestingly, although side population (SP) cells isolated from RPMI8226 cells exhibited higher levels of glycolysis with an increased expression of genes involved in the glycolytic pathway, 3BrPA abolished Hoechst 33342 exclusion in SP cells. 3BrPA also disrupted clonogenic capacity in malignant cell lines including RPMI8226, KG-1, and HepG2. Furthermore, 3BrPA restored cytotoxic effects of daunorubicin and doxorubicin on KG-1 and RPMI8226 cells, and markedly suppressed subcutaneous tumor growth in combination with doxorubicin in RPMI8226-implanted mice. These results collectively suggest that the inhibition of glycolysis is able to overcome drug resistance in ABC transporter-expressing malignant cells through the inactivation of ABC transporters and impairment of SP cells with enhanced glycolysis as well as clonogenic cells.","ja":"Cancer cells eventually acquire drug resistance largely via the aberrant expression of ATP-binding cassette (ABC) transporters, ATP-dependent efflux pumps. Because cancer cells produce ATP mostly through glycolysis, in the present study we explored the effects of inhibiting glycolysis on the ABC transporter function and drug sensitivity of malignant cells. Inhibition of glycolysis by 3-bromopyruvate (3BrPA) suppressed ATP production in malignant cells, and restored the retention of daunorubicin or mitoxantrone in ABC transporter-expressing, RPMI8226 (ABCG2), KG-1 (ABCB1) and HepG2 cells (ABCB1 and ABCG2). Interestingly, although side population (SP) cells isolated from RPMI8226 cells exhibited higher levels of glycolysis with an increased expression of genes involved in the glycolytic pathway, 3BrPA abolished Hoechst 33342 exclusion in SP cells. 3BrPA also disrupted clonogenic capacity in malignant cell lines including RPMI8226, KG-1, and HepG2. Furthermore, 3BrPA restored cytotoxic effects of daunorubicin and doxorubicin on KG-1 and RPMI8226 cells, and markedly suppressed subcutaneous tumor growth in combination with doxorubicin in RPMI8226-implanted mice. These results collectively suggest that the inhibition of glycolysis is able to overcome drug resistance in ABC transporter-expressing malignant cells through the inactivation of ABC transporters and impairment of SP cells with enhanced glycolysis as well as clonogenic cells."},"publication_date":"2011-11-02","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"6","number":"11","starting_page":"e27222","ending_page":"e27222","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pone.0027222"],"issn":["1932-6203"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:23, {"insert":{"user_id":"B000341201","type":"published_papers","id":"15167274"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/21902681","label":"url"},{"@id":"https://www.scopus.com/pages/publications/80053987418","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=248823","label":"url"}],"paper_title":{"en":"KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.","ja":"KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts."},"authors":{"en":[{"name":"Miki Hirokazu"},{"name":"Nakamura Shingen"},{"name":"Ozaki Shuji"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"Ikegame Akishige"},{"name":"Watanabe Keiichiro"},{"name":"Hiasa Masahiro"},{"name":"Cui Qu"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Nakano Ayako"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Yata Ken-ichiro"},{"name":"Sakai Akira"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"}],"ja":[{"name":"三木 浩和"},{"name":"中村 信元"},{"name":"尾崎 修治"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"池亀 彰茂"},{"name":"渡邉 佳一郎"},{"name":"日浅 雅博"},{"name":"Cui Qu"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"Nakano Ayako"},{"name":"賀川 久美子"},{"name":"竹内 恭子"},{"name":"矢田 健一郎"},{"name":"Sakai Akira"},{"name":"安倍 正博"},{"name":"松本 俊夫"}]},"description":{"en":"The spicamycin analogue KRN5500 alters glycoprotein processing and induces damage in the endoplasmic reticulum (ER)-Golgi apparatus in cancer cells. In the present study, we explored the cytotoxic effects of KRN5500 on multiple myeloma (MM) cells and the bone marrow microenvironment with special reference to ER stress. Cell proliferation assay showed that KRN5500 induced G1 arrest and apoptosis in MM cells in a time- and dose-dependent manner. KRN5500 enhanced ER stress independently of caspase activation in MM cells. This cell death was observed even in the presence of bone marrow stroma cells or osteoclasts. Notably, KRN5500 induced cell death also in osteoclasts. In vivo effects of KRN5500 were evaluated using two xenograft models established in severe combined immunodeficient (SCID) mice by either subcutaneous injection of RPMI 8226 cells or intra-bone injection of INA-6 cells to subcutaneously implanted rabbit bones (SCID-rab model). KRN5500 significantly inhibited tumour growth in both animal models, and decreased the number of osteoclasts, which resulted in prevention of bone destruction in the SCID-rab model. These results suggest that KRN5500 exerts anti-MM effects through impairing both MM cells and osteoclasts. Therefore, this unique mechanism of KRN5500 might be a useful therapeutic option in patients with MM.","ja":"The spicamycin analogue KRN5500 alters glycoprotein processing and induces damage in the endoplasmic reticulum (ER)-Golgi apparatus in cancer cells. In the present study, we explored the cytotoxic effects of KRN5500 on multiple myeloma (MM) cells and the bone marrow microenvironment with special reference to ER stress. Cell proliferation assay showed that KRN5500 induced G1 arrest and apoptosis in MM cells in a time- and dose-dependent manner. KRN5500 enhanced ER stress independently of caspase activation in MM cells. This cell death was observed even in the presence of bone marrow stroma cells or osteoclasts. Notably, KRN5500 induced cell death also in osteoclasts. In vivo effects of KRN5500 were evaluated using two xenograft models established in severe combined immunodeficient (SCID) mice by either subcutaneous injection of RPMI 8226 cells or intra-bone injection of INA-6 cells to subcutaneously implanted rabbit bones (SCID-rab model). KRN5500 significantly inhibited tumour growth in both animal models, and decreased the number of osteoclasts, which resulted in prevention of bone destruction in the SCID-rab model. These results suggest that KRN5500 exerts anti-MM effects through impairing both MM cells and osteoclasts. Therefore, this unique mechanism of KRN5500 might be a useful therapeutic option in patients with MM."},"publication_date":"2011-11","publication_name":{"en":"British Journal of Haematology","ja":"British Journal of Haematology"},"volume":"155","number":"3","starting_page":"328","ending_page":"339","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/j.1365-2141.2011.08844.x"],"issn":["1365-2141"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:24, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/21526377","label":"url"},{"@id":"https://www.scopus.com/pages/publications/79960091205","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=229235","label":"url"}],"paper_title":{"en":"Delayed treatment with vitamin C and N-acetyl-L: -cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.","ja":"Delayed treatment with vitamin C and N-acetyl-L: -cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib."},"authors":{"en":[{"name":"Nakano Ayako"},{"name":"Abe Masahiro"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"Hiasa Masahiro"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Harada Takeshi"},{"name":"Fujii Shirou"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Watanabe Takashi"},{"name":"Ozaki Shuji"},{"name":"Matsumoto Toshio"}],"ja":[{"name":"Nakano Ayako"},{"name":"安倍 正博"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"日浅 雅博"},{"name":"中村 信元"},{"name":"Miki Hirokazu"},{"name":"原田 武志"},{"name":"Fujii Shirou"},{"name":"賀川 久美子"},{"name":"竹内 恭子"},{"name":"Watanabe Takashi"},{"name":"尾崎 修治"},{"name":"松本 俊夫"}]},"description":{"en":"Bortezomib-induced peripheral neuropathy (BIPN) emerges as a disabling adverse effect. As rat models for BIPN have demonstrated damage in nerve Schwann cells, we screened for cytoprotective agents to devise a method of rescuing Schwann cells from the cytotoxic effects of bortezomib without compromising its anti-myeloma effects. Schwann cells underwent macroautophagy along with cytoplasmic inclusion body and vacuole formation, and appeared much less susceptible to bortezomib-induced cytotoxicity than did myeloma cells. Vitamin C or N-acetyl-L: -cysteine (NAC) achieved near-complete rescue of Schwann cells treated with bortezomib at 30 nM or less, and these agents in combination are able to cooperatively inhibit the morphological changes and the cytotoxicity in Schwann cells with higher doses of bortezomib. The delayed addition of vitamin C and/or NAC after the exposure to bortezomib alleviated the cytotoxicity in Schwann cells but not myeloma cells. These results suggest that delayed treatment with these agents may be instrumental in prophylaxis of BIPN.","ja":"Bortezomib-induced peripheral neuropathy (BIPN) emerges as a disabling adverse effect. As rat models for BIPN have demonstrated damage in nerve Schwann cells, we screened for cytoprotective agents to devise a method of rescuing Schwann cells from the cytotoxic effects of bortezomib without compromising its anti-myeloma effects. Schwann cells underwent macroautophagy along with cytoplasmic inclusion body and vacuole formation, and appeared much less susceptible to bortezomib-induced cytotoxicity than did myeloma cells. Vitamin C or N-acetyl-L: -cysteine (NAC) achieved near-complete rescue of Schwann cells treated with bortezomib at 30 nM or less, and these agents in combination are able to cooperatively inhibit the morphological changes and the cytotoxicity in Schwann cells with higher doses of bortezomib. The delayed addition of vitamin C and/or NAC after the exposure to bortezomib alleviated the cytotoxicity in Schwann cells but not myeloma cells. These results suggest that delayed treatment with these agents may be instrumental in prophylaxis of BIPN."},"publication_date":"2011-04-28","publication_name":{"en":"International Journal of Hematology","ja":"International Journal of Hematology"},"volume":"93","number":"6","starting_page":"727","ending_page":"735","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12185-011-0850-7"],"issn":["1865-3774"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:25, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2002336","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/21475253","label":"url"},{"@id":"https://www.scopus.com/pages/publications/79960240251","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=229236","label":"url"}],"paper_title":{"en":"The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.","ja":"The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells."},"authors":{"en":[{"name":"Asano J"},{"name":"Nakano A"},{"name":"Oda A"},{"name":"Amou H"},{"name":"Hiasa Masahiro"},{"name":"Takeuchi Kyoko"},{"name":"Miki Hirokazu"},{"name":"Nakamura Shingen"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Kagawa Kumiko"},{"name":"Endo Itsuro"},{"name":"Yata Ken-ichiro"},{"name":"Sakai A"},{"name":"Ozaki Shuji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"Asano J"},{"name":"Nakano A"},{"name":"Oda A"},{"name":"Amou H"},{"name":"日浅 雅博"},{"name":"竹内 恭子"},{"name":"三木 浩和"},{"name":"中村 信元"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"賀川 久美子"},{"name":"遠藤 逸朗"},{"name":"矢田 健一郎"},{"name":"Sakai A"},{"name":"尾崎 修治"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"Bone marrow stromal cells (BMSCs) and osteoclasts (OCs) confer multiple myeloma (MM) cell survival through elaborating factors. We demonstrate herein that IL-6 and TNF family cytokines, TNF, BAFF and APRIL, but not IGF-1 cooperatively enhance the expression of the serine/threonine kinase Pim-2 in MM cells. BMSCs and OCs upregulate Pim-2 expression in MM cells largely via the IL-6/STAT3 and NF-B pathway, respectively. Pim-2 short interfering RNA reduces MM cell viability in cocultures with BMSCs or OCs. Thus, upregulation of Pim-2 appears to be a novel anti-apoptotic mechanism for MM cell survival. Interestingly, the mammalian target of rapamycin inhibitor rapamycin further suppresses the MM cell viability in combination with the Pim-2 silencing. The Pim inhibitor (Z)-5-(4-propoxybenzylidene) thiazolidine-2, 4-dione and the PI3K inhibitor LY294002 cooperatively enhance MM cell death. The Pim inhibitor suppresses 4E-BP1 phosphorylation along with the reduction of Mcl-1 and c-Myc. Pim-2 may therefore become a new target for MM treatment.Leukemia advance online publication, 8 April 2011; doi:10.1038/leu.2011.60.","ja":"Bone marrow stromal cells (BMSCs) and osteoclasts (OCs) confer multiple myeloma (MM) cell survival through elaborating factors. We demonstrate herein that IL-6 and TNF family cytokines, TNF, BAFF and APRIL, but not IGF-1 cooperatively enhance the expression of the serine/threonine kinase Pim-2 in MM cells. BMSCs and OCs upregulate Pim-2 expression in MM cells largely via the IL-6/STAT3 and NF-B pathway, respectively. Pim-2 short interfering RNA reduces MM cell viability in cocultures with BMSCs or OCs. Thus, upregulation of Pim-2 appears to be a novel anti-apoptotic mechanism for MM cell survival. Interestingly, the mammalian target of rapamycin inhibitor rapamycin further suppresses the MM cell viability in combination with the Pim-2 silencing. The Pim inhibitor (Z)-5-(4-propoxybenzylidene) thiazolidine-2, 4-dione and the PI3K inhibitor LY294002 cooperatively enhance MM cell death. The Pim inhibitor suppresses 4E-BP1 phosphorylation along with the reduction of Mcl-1 and c-Myc. Pim-2 may therefore become a new target for MM treatment.Leukemia advance online publication, 8 April 2011; doi:10.1038/leu.2011.60."},"publication_date":"2011-04-08","publication_name":{"en":"Leukemia","ja":"Leukemia"},"volume":"25","starting_page":"1182","ending_page":"1188","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/leu.2011.60"],"issn":["1476-5551"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:26, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://ci.nii.ac.jp/naid/130004501433/","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/20805677","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390001205037088512/","label":"url"},{"@id":"https://www.scopus.com/pages/publications/78349258607","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=432018","label":"url"}],"paper_title":{"en":"[Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].","ja":"ボルテゾミブ療法後に播種性接合菌症を合併した多発性骨髄腫"},"authors":{"en":[{"name":"Nakamura Shingen"},{"name":"Yata Kenichiro"},{"name":"Jinno Tadashi"},{"name":"Harada Takeshi"},{"name":"Fujii Shiro"},{"name":"Miki Hirokazu"},{"name":"Nakano Ayako"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Ozaki Shuji"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"}],"ja":[{"name":"中村 信元"},{"name":"Yata Kenichiro"},{"name":"Jinno Tadashi"},{"name":"原田 武志"},{"name":"Fujii Shiro"},{"name":"Miki Hirokazu"},{"name":"Nakano Ayako"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Ozaki Shuji"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"}]},"description":{"en":"A 67-year-old man was diagnosed with multiple myeloma IgA-lambda type, Durie-Salmon classification stage IIIA in October 2001. He received five courses of induction chemotherapy consisting of vincristine, doxorubicin and dexamethasone and then underwent high dose chemotherapy followed by autologous stem cell transplantation in March 2003. He achieved partial response, but then relapsed after treatment with thalidomide and was admitted to our hospital in June 2007. The patient was complicated by tumor lysis syndrome (TLS) after receiving bortezomib therapy twice. Computed tomography after bortezomib therapy showed the rapid appearance of tumors in the right upper lobe of the lung, tail of the pancreas and the spleen. Though he was treated with antifungal agents, micafungin and voriconazole, he died eighty-five days after admission. Autopsy specimen showed fungal clumps and hemorrhagic infarction in the lung and spleen, and vegetation at the mitral valve was the same fungus as found in the lung. We diagnosed disseminated zygomycosis based on the pathological fungal morphology. This case suggested that metabolic acidosis was caused by TLS, while poorly controlled diabetes, secondary hemochromatosis due to transfusion, and breakthrough zygomycosis during antifungal therapy were thought to be factors contributing to the development of zygomycosis.","ja":"67歳男性，背部痛を契機に2001年10月に多発性骨髄腫IgA-<i>λ</i> stage IIIAと診断された．VAD療法5コース後の2003年3月に自家末梢血幹細胞移植併用大量化学療法を行うも再発した．以後，サリドマイド療法などを行うも再燃し，2007年6月入院した．入院後のボルテゾミブ(Bor)療法で，2度の腫瘍崩壊症候群をきたした．その後のCTで右肺上葉，膵尾部，脾臓の腫瘤が急速に出現し，ミカファンギンやボリコナゾールを投与するも，入院85日後に死亡した．剖検で，肺，脾臓に多発性の真菌塊と出血性梗塞が認められ，僧帽弁には真菌塊の疣贅を認め，組織学的に播種性接合菌症と診断した．Bor療法後の腫瘍崩壊によるアシドーシスや，コントロール不良の糖尿病，輸血による鉄過剰，抗真菌薬投与中のブレークスルー感染症などが発症の誘因と考えられた．"},"publication_date":"2010-08","publication_name":{"en":"The Japanese Journal of Clinical Hematology","ja":"臨床血液"},"volume":"51","number":"8","starting_page":"690","ending_page":"695","languages":["jpn"],"referee":true,"identifiers":{"doi":["10.11406/rinketsu.51.690"],"issn":["0485-1439"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:27, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2000254","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/20360846","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=209846","label":"url"}],"paper_title":{"en":"Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.","ja":"Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth."},"authors":{"en":[{"name":"Takeuchi Kyoko"},{"name":"Abe Masahiro"},{"name":"Hiasa Masahiro"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"Kido Shinsuke"},{"name":"Harada Takeshi"},{"name":"Tanaka Osamu"},{"name":"Miki Hirokazu"},{"name":"Nakamura Shingen"},{"name":"Nakano Ayako"},{"name":"Kagawa Kumiko"},{"name":"Yata Kenichiro"},{"name":"Ozaki Shuji"},{"name":"Matsumoto Toshio"}],"ja":[{"name":"竹内 恭子"},{"name":"安倍 正博"},{"name":"日浅 雅博"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"木戸 慎介"},{"name":"原田 武志"},{"name":"Tanaka Osamu"},{"name":"三木 浩和"},{"name":"中村 信元"},{"name":"Nakano Ayako"},{"name":"賀川 久美子"},{"name":"Yata Kenichiro"},{"name":"尾崎 修治"},{"name":"松本 俊夫"}]},"description":{"en":"BACKGROUND: Multiple myeloma (MM) expands almost exclusively in the bone marrow and generates devastating bone lesions, in which bone formation is impaired and osteoclastic bone resorption is enhanced. TGF-beta, a potent inhibitor of terminal osteoblast (OB) differentiation, is abundantly deposited in the bone matrix, and released and activated by the enhanced bone resorption in MM. The present study was therefore undertaken to clarify the role of TGF-beta and its inhibition in bone formation and tumor growth in MM. METHODOLOGY/PRINCIPAL FINDINGS: TGF-beta suppressed OB differentiation from bone marrow stromal cells and MC3T3-E1 preosteoblastic cells, and also inhibited adipogenesis from C3H10T1/2 immature mesenchymal cells, suggesting differentiation arrest by TGF-beta. Inhibitors for a TGF-beta type I receptor kinase, SB431542 and Ki26894, potently enhanced OB differentiation from bone marrow stromal cells as well as MC3T3-E1 cells. The TGF-beta inhibition was able to restore OB differentiation suppressed by MM cell conditioned medium as well as bone marrow plasma from MM patients. Interestingly, TGF-beta inhibition expedited OB differentiation in parallel with suppression of MM cell growth. The anti-MM activity was elaborated exclusively by terminally differentiated OBs, which potentiated the cytotoxic effects of melphalan and dexamethasone on MM cells. Furthermore, TGF-beta inhibition was able to suppress MM cell growth within the bone marrow while preventing bone destruction in MM-bearing animal models. CONCLUSIONS/SIGNIFICANCE: The present study demonstrates that TGF-beta inhibition releases stromal cells from their differentiation arrest by MM and facilitates the formation of terminally differentiated OBs, and that terminally differentiated OBs inhibit MM cell growth and survival and enhance the susceptibility of MM cells to anti-MM agents to overcome the drug resistance mediated by stromal cells. Therefore, TGF-beta appears to be an important therapeutic target in MM bone lesions.","ja":"BACKGROUND: Multiple myeloma (MM) expands almost exclusively in the bone marrow and generates devastating bone lesions, in which bone formation is impaired and osteoclastic bone resorption is enhanced. TGF-beta, a potent inhibitor of terminal osteoblast (OB) differentiation, is abundantly deposited in the bone matrix, and released and activated by the enhanced bone resorption in MM. The present study was therefore undertaken to clarify the role of TGF-beta and its inhibition in bone formation and tumor growth in MM. METHODOLOGY/PRINCIPAL FINDINGS: TGF-beta suppressed OB differentiation from bone marrow stromal cells and MC3T3-E1 preosteoblastic cells, and also inhibited adipogenesis from C3H10T1/2 immature mesenchymal cells, suggesting differentiation arrest by TGF-beta. Inhibitors for a TGF-beta type I receptor kinase, SB431542 and Ki26894, potently enhanced OB differentiation from bone marrow stromal cells as well as MC3T3-E1 cells. The TGF-beta inhibition was able to restore OB differentiation suppressed by MM cell conditioned medium as well as bone marrow plasma from MM patients. Interestingly, TGF-beta inhibition expedited OB differentiation in parallel with suppression of MM cell growth. The anti-MM activity was elaborated exclusively by terminally differentiated OBs, which potentiated the cytotoxic effects of melphalan and dexamethasone on MM cells. Furthermore, TGF-beta inhibition was able to suppress MM cell growth within the bone marrow while preventing bone destruction in MM-bearing animal models. CONCLUSIONS/SIGNIFICANCE: The present study demonstrates that TGF-beta inhibition releases stromal cells from their differentiation arrest by MM and facilitates the formation of terminally differentiated OBs, and that terminally differentiated OBs inhibit MM cell growth and survival and enhance the susceptibility of MM cells to anti-MM agents to overcome the drug resistance mediated by stromal cells. Therefore, TGF-beta appears to be an important therapeutic target in MM bone lesions."},"publication_date":"2010-03-25","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"5","number":"3","starting_page":"e9870","ending_page":"e9870","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pone.0009870"],"issn":["1932-6203"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:28, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/19225725","label":"url"},{"@id":"https://www.scopus.com/pages/publications/67349204419","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=434711","label":"url"}],"paper_title":{"en":"Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma","ja":"Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma"},"authors":{"en":[{"name":"Miki Hirokazu"},{"name":"Ozaki Shuji"},{"name":"Tanaka Osamu"},{"name":"Lee Etsuko"},{"name":"Takimoto Tomomi"},{"name":"Watanabe Hirofumi"},{"name":"Fujii Shiro"},{"name":"Nakamura Shingen"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Yata Ken Ichiro"},{"name":"Abe Masahiro"},{"name":"Kagami Shoji"},{"name":"Matsumoto Toshio"}],"ja":[{"name":"Miki Hirokazu"},{"name":"Ozaki Shuji"},{"name":"Tanaka Osamu"},{"name":"Lee Etsuko"},{"name":"Takimoto Tomomi"},{"name":"Watanabe Hirofumi"},{"name":"Fujii Shiro"},{"name":"中村 信元"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Yata Ken Ichiro"},{"name":"Abe Masahiro"},{"name":"Kagami Shoji"},{"name":"Matsumoto Toshio"}]},"description":{"en":"We report a patient with refractory multiple myeloma (MM) who developed platelet transfusion refractoriness (PTR). A 61-year-old woman was diagnosed with MM in July 2003. She underwent high-dose chemotherapy followed by autologous stem cell transplantation, and achieved a very good partial response. However, she relapsed in June 2006, and was referred to our hospital in October of the same year. Laboratory examinations showed pancytopenia and increased plasma cells in the peripheral blood. Platelet transfusions from random donors became ineffective, and anti-HLA class I antibody (83.8% positive) was detected in the serum by flow cytometry assay (Flow PRA). Therefore, she was considered to have developed PTR due to anti-HLA class I antibody caused by the previous blood transfusions. She was transfused with HLA-matched platelets, and then treated with bortezomib plus dexamethasone (BD) for refractory MM. The serum IgG level decreased from 7,451 to 1,735 mg/dL, and HLA class I antibody was markedly decreased to 1.9%. In addition, platelet transfusion from random donors showed clinical effects after BD therapy. This case suggests that bortezomib might be effective in different types of immune disease by inhibiting allo-reactive antibody.","ja":"We report a patient with refractory multiple myeloma (MM) who developed platelet transfusion refractoriness (PTR). A 61-year-old woman was diagnosed with MM in July 2003. She underwent high-dose chemotherapy followed by autologous stem cell transplantation, and achieved a very good partial response. However, she relapsed in June 2006, and was referred to our hospital in October of the same year. Laboratory examinations showed pancytopenia and increased plasma cells in the peripheral blood. Platelet transfusions from random donors became ineffective, and anti-HLA class I antibody (83.8% positive) was detected in the serum by flow cytometry assay (Flow PRA). Therefore, she was considered to have developed PTR due to anti-HLA class I antibody caused by the previous blood transfusions. She was transfused with HLA-matched platelets, and then treated with bortezomib plus dexamethasone (BD) for refractory MM. The serum IgG level decreased from 7,451 to 1,735 mg/dL, and HLA class I antibody was markedly decreased to 1.9%. In addition, platelet transfusion from random donors showed clinical effects after BD therapy. This case suggests that bortezomib might be effective in different types of immune disease by inhibiting allo-reactive antibody."},"publication_date":"2009-02-20","publication_name":{"en":"International Journal of Hematology","ja":"International Journal of Hematology"},"volume":"89","number":"2","starting_page":"223","ending_page":"226","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12185-009-0255-z"],"issn":["0925-5710"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:29, {"insert":{"user_id":"B000341201","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/21279817","label":"url"},{"@id":"https://www.scopus.com/pages/publications/79952252906","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=431081","label":"url"}],"paper_title":{"en":"Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma","ja":"Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma"},"authors":{"en":[{"name":"Ozaki Shuji"},{"name":"Harada Takeshi"},{"name":"Fujii Shiro"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Nakano Ayako"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"}],"ja":[{"name":"Ozaki Shuji"},{"name":"原田 武志"},{"name":"Fujii Shiro"},{"name":"中村 信元"},{"name":"Miki Hirokazu"},{"name":"Nakano Ayako"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"}]},"publication_date":"2011-02-01","publication_name":{"en":"International Journal of Hematology","ja":"International Journal of Hematology"},"volume":"93","number":"2","starting_page":"257","ending_page":"259","languages":["eng"],"identifiers":{"doi":["10.1007/s12185-011-0775-1"],"issn":["0925-5710"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
==== end registerFile(/WWW/pub2/data/ERD/person/229265/researchmap/published_papers-propagate.jsonl, KsYgrKABRJbN-uhaijxc) ====
EID=466276 is rejected. (Reason: タイトルが登録されていません．)
==== begin registerFile(/WWW/pub2/data/ERD/person/229265/researchmap/presentations-propagate.jsonl) ====
line:1, {"insert":{"user_id":"B000341201","type":"presentations","id":"1738077"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=269242","label":"url"}],"presentation_title":{"en":"Combination therapy of a defucosylated anti-HM1.24 monoclonal antibody plus Ienalidomide induces marked antibody-dependent cellular cytotoxicity and inhibits the clonogenic potential of myeloma cancer stem-like cells. Atlanta, Dec. 2012.","ja":"Combination therapy of a defucosylated anti-HM1.24 monoclonal antibody plus Ienalidomide induces marked antibody-dependent cellular cytotoxicity and inhibits the clonogenic potential of myeloma cancer stem-like cells. Atlanta, Dec. 2012."},"presenters":{"en":[{"name":"Harada Takeshi"},{"name":"Ozaki Shuji"},{"name":"Oda Asuka"},{"name":"Iwasa Masami"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Abe Masahiro"},{"name":"Shibata Hironobu"},{"name":"Ikegame Akishige"},{"name":"Tsuji Daisuke"},{"name":"Ito Kohji"},{"name":"Ri Masaki"},{"name":"Iida Shinsuke"},{"name":"Shiotsu Yukimasa"},{"name":"Kawai Shigeto"},{"name":"Yamada-Okabe Hisafumi"},{"name":"Matsumoto Toshio"}],"ja":[{"name":"Harada Takeshi"},{"name":"Ozaki Shuji"},{"name":"Oda Asuka"},{"name":"Iwasa Masami"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"安倍 正博"},{"name":"Shibata Hironobu"},{"name":"池亀 彰茂"},{"name":"辻 大輔"},{"name":"Ito Kohji"},{"name":"Ri Masaki"},{"name":"Iida Shinsuke"},{"name":"Shiotsu Yukimasa"},{"name":"Kawai Shigeto"},{"name":"Yamada-Okabe Hisafumi"},{"name":"松本 俊夫"}]},"event":{"en":"The 54th Annual Meeting of the American Society of Hamatology","ja":"The 54th Annual Meeting of the American Society of Hamatology"},"publication_date":"2012-12-08","languages":["eng"],"is_international_presentation":true},"priority":"input_data"}
line:2, {"insert":{"user_id":"B000341201","type":"presentations","id":"47364782"},"force":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/Y522310423","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=412165","label":"url"}],"presentation_title":{"en":"赤血球のmean corpuscular volumeと代謝異常関連脂肪肝疾患の連関解析","ja":"赤血球のmean corpuscular volumeと代謝異常関連脂肪肝疾患の連関解析"},"presenters":{"en":[{"name":"金子 遥祐"},{"name":"河田 沙紀"},{"name":"森 建介"},{"name":"細木 美苗"},{"name":"Hori Taiki"},{"name":"辻 誠士郎"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Nakamura Shingen"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"金子 遥祐"},{"name":"河田 沙紀"},{"name":"森 建介"},{"name":"細木 美苗"},{"name":"堀 太貴"},{"name":"辻 誠士郎"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"中村 信元"},{"name":"粟飯原 賢一"}]},"event":{"en":"Folia endocrinologica Japonica","ja":"日本内分泌学会雑誌"},"publication_date":"2024-05","languages":["jpn"],"promoter":{"en":"(一社)日本内分泌学会","ja":"(一社)日本内分泌学会"},"is_international_presentation":false},"priority":"input_data"}
line:3, {"insert":{"user_id":"B000341201","type":"presentations","id":"47364783"},"force":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/Y522310478","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=412163","label":"url"}],"presentation_title":{"en":"2型糖尿病患者の糖尿病性腎臓病における推定食塩摂取量の意義","ja":"2型糖尿病患者の糖尿病性腎臓病における推定食塩摂取量の意義"},"presenters":{"en":[{"name":"Aihara Ken-ichi"},{"name":"三宅 南帆"},{"name":"辻 誠士郎"},{"name":"河田 沙紀"},{"name":"Nakamura Shingen"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"}],"ja":[{"name":"粟飯原 賢一"},{"name":"三宅 南帆"},{"name":"辻 誠士郎"},{"name":"河田 沙紀"},{"name":"中村 信元"},{"name":"乙田 敏城"},{"name":"湯浅 智之"}]},"event":{"en":"Folia endocrinologica Japonica","ja":"日本内分泌学会雑誌"},"publication_date":"2024-05","languages":["jpn"],"promoter":{"en":"(一社)日本内分泌学会","ja":"(一社)日本内分泌学会"},"is_international_presentation":false},"priority":"input_data"}
line:4, {"insert":{"user_id":"B000341201","type":"presentations","id":"47364784"},"force":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/Y604210084","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=412161","label":"url"}],"presentation_title":{"en":"KRAS変異を認めた治療抵抗性Rosai-Dorfman病の1例","ja":"KRAS変異を認めた治療抵抗性Rosai-Dorfman病の1例"},"presenters":{"en":[{"name":"Sumitani Ryohei"},{"name":"Miki Hirokazu"},{"name":"Okamura Kazumi"},{"name":"前田 悠作"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"八木 ひかる"},{"name":"高橋 真美子"},{"name":"丸橋 朋子"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Oya Takeshi"},{"name":"Abe Masahiro"},{"name":"佐藤 亜紀"}],"ja":[{"name":"住谷 龍平"},{"name":"三木 浩和"},{"name":"岡村 和美"},{"name":"前田 悠作"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"八木 ひかる"},{"name":"高橋 真美子"},{"name":"丸橋 朋子"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"尾矢 剛志"},{"name":"安倍 正博"},{"name":"佐藤 亜紀"}]},"event":{"en":"The Japanese Journal of Clinical Hematology","ja":"臨床血液"},"publication_date":"2024-05","languages":["jpn"],"promoter":{"en":"(一社)日本血液学会-東京事務局","ja":"(一社)日本血液学会-東京事務局"},"is_international_presentation":false},"priority":"input_data"}
line:5, {"insert":{"user_id":"B000341201","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402667","label":"url"}],"presentation_title":{"en":"周期的な発熱，血小板減少，高LDH血症で発症したびまん性大細胞型B細胞リンパ腫の1例","ja":"周期的な発熱，血小板減少，高LDH血症で発症したびまん性大細胞型B細胞リンパ腫の1例"},"presenters":{"en":[{"name":"Sumitani Ryohei"},{"name":"Nakamura Shingen"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"髙橋 真美子"},{"name":"Fujii Shiroh"},{"name":"Harada Takeshi"},{"name":"Miki Hirokazu"},{"name":"Abe Masahiro"}],"ja":[{"name":"住谷 龍平"},{"name":"中村 信元"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"髙橋 真美子"},{"name":"藤井 志朗"},{"name":"原田 武志"},{"name":"三木 浩和"},{"name":"安倍 正博"}]},"event":{"en":"第128回日本内科学会四国地方会","ja":"第128回日本内科学会四国地方会"},"publication_date":"2023-07","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:6, {"insert":{"user_id":"B000341201","type":"presentations","id":"39550744"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388257","label":"url"}],"presentation_title":{"en":"免疫不全リスクを有する患者における 新型コロナワクチンによる抗体獲得能に 関連する因子の検討","ja":"免疫不全リスクを有する患者における 新型コロナワクチンによる抗体獲得能に 関連する因子の検討"},"presenters":{"en":[{"name":"Okada Naoto"},{"name":"Nakamura Shingen"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Aizawa Fuka"},{"name":"Niimura Takahiro"},{"name":"Yagi Kenta"},{"name":"Goda Mitsuhiro"},{"name":"Ishida Tatsuhiro"},{"name":"Ishizawa Keisuke"}],"ja":[{"name":"岡田 直人"},{"name":"中村 信元"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"相澤 風花"},{"name":"新村 貴博"},{"name":"八木 健太"},{"name":"合田 光寛"},{"name":"石田 竜弘"},{"name":"石澤 啓介"}]},"event":{"en":"第32回日本医療薬学学会","ja":"第32回日本医療薬学学会"},"publication_date":"2022-09-23","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:7, {"insert":{"user_id":"B000341201","type":"presentations","id":"39550746"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388259","label":"url"}],"presentation_title":{"en":"新型コロナワクチン接種後に発覚した自己免疫性出血病FXIII/13","ja":"新型コロナワクチン接種後に発覚した自己免疫性出血病FXIII/13"},"presenters":{"en":[{"name":"Nakamura Shingen"},{"name":"Hori Taiki"},{"name":"Hosoki Minae"},{"name":"Yasui Saya"},{"name":"Yamagami Hiroki"},{"name":"赤澤 啓人"},{"name":"滝下 誠"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"中村 信元"},{"name":"堀 太貴"},{"name":"細木 美苗"},{"name":"安井 沙耶"},{"name":"山上 紘規"},{"name":"赤澤 啓人"},{"name":"滝下 誠"},{"name":"粟飯原 賢一"}]},"event":{"en":"第126回日本内科学会四国地方会","ja":"第126回日本内科学会四国地方会"},"publication_date":"2022-06-05","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:8, {"insert":{"user_id":"B000341201","type":"presentations","id":"39550747"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388258","label":"url"}],"presentation_title":{"en":"地域での造血腫瘍の診療を考える","ja":"地域での造血腫瘍の診療を考える"},"presenters":{"en":[{"name":"本田 壮一"},{"name":"Nakamura Shingen"},{"name":"高橋 啓輝"},{"name":"Hori Taiki"},{"name":"Abe Masahiro"}],"ja":[{"name":"本田 壮一"},{"name":"中村 信元"},{"name":"高橋 啓輝"},{"name":"堀 太貴"},{"name":"安倍 正博"}]},"event":{"en":"第126回日本内科学会四国地方会","ja":"第126回日本内科学会四国地方会"},"publication_date":"2022-06-05","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:9, {"insert":{"user_id":"B000341201","type":"presentations","id":"39550748"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388265","label":"url"}],"presentation_title":{"en":"血液疾患，自己免疫疾患における新型コロナワクチン接種後の抗体獲得能の検討","ja":"血液疾患，自己免疫疾患における新型コロナワクチン接種後の抗体獲得能の検討"},"presenters":{"en":[{"name":"Nakamura Shingen"},{"name":"Hori Taiki"},{"name":"Hosoki Minae"},{"name":"Yasui Saya"},{"name":"Yamagami Hiroki"},{"name":"滝下 誠"},{"name":"答島 章公"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"中村 信元"},{"name":"堀 太貴"},{"name":"細木 美苗"},{"name":"安井 沙耶"},{"name":"山上 紘規"},{"name":"滝下 誠"},{"name":"答島 章公"},{"name":"粟飯原 賢一"}]},"event":{"en":"第96回日本感染症学会総会","ja":"第96回日本感染症学会総会"},"publication_date":"2022-05-22","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:10, {"insert":{"user_id":"B000341201","type":"presentations","id":"39550749"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388264","label":"url"}],"presentation_title":{"en":"Humoral response of the mRNA vaccine against SARS-CoV-2 in patients with plasma cell dyscrasia","ja":"Humoral response of the mRNA vaccine against SARS-CoV-2 in patients with plasma cell dyscrasia"},"presenters":{"en":[{"name":"Nakamura Shingen"},{"name":"Hori Taiki"},{"name":"Nakamura Masafumi"},{"name":"Sumitani Ryohei"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Maruhashi Tomoko"},{"name":"高橋 真美子"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Harada Takeshi"},{"name":"Abe Masahiro"}],"ja":[{"name":"中村 信元"},{"name":"堀 太貴"},{"name":"中村 昌史"},{"name":"住谷 龍平"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"丸橋 朋子"},{"name":"高橋 真美子"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"原田 武志"},{"name":"安倍 正博"}]},"event":{"en":"The 47th annual meeting of Japanese Society of Myeloma","ja":"The 47th annual meeting of Japanese Society of Myeloma"},"publication_date":"2022-05-22","languages":["eng"],"is_international_presentation":false},"priority":"input_data"}
line:11, {"insert":{"user_id":"B000341201","type":"presentations","id":"39550750"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388256","label":"url"}],"presentation_title":{"en":"自己免疫疾患における新型コロナワクチンによる抗体獲得能の検討","ja":"自己免疫疾患における新型コロナワクチンによる抗体獲得能の検討"},"presenters":{"en":[{"name":"Yamagami Hiroki"},{"name":"Nakamura Shingen"},{"name":"Tani Akihiro"},{"name":"Hosoki Minae"},{"name":"Yasui Saya"},{"name":"Miyata Yoshihiro"},{"name":"Hori Taiki"},{"name":"答島 章公"},{"name":"Aihara Ken-ichi"},{"name":"滝下 誠"}],"ja":[{"name":"山上 紘規"},{"name":"中村 信元"},{"name":"谷 彰浩"},{"name":"細木 美苗"},{"name":"安井 沙耶"},{"name":"宮田 好裕"},{"name":"堀 太貴"},{"name":"答島 章公"},{"name":"粟飯原 賢一"},{"name":"滝下 誠"}]},"event":{"en":"第119回日本内科学会総会","ja":"第119回日本内科学会総会"},"publication_date":"2022-04-17","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:12, {"insert":{"user_id":"B000341201","type":"presentations","id":"39550751"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388255","label":"url"}],"presentation_title":{"en":"血液疾患患者における新型コロナウイルスワクチン接種による抗体獲得能の検討","ja":"血液疾患患者における新型コロナウイルスワクチン接種による抗体獲得能の検討"},"presenters":{"en":[{"name":"Hori Taiki"},{"name":"Nakamura Shingen"},{"name":"Tani Akihiro"},{"name":"Hosoki Minae"},{"name":"Yasui Saya"},{"name":"Miyata Yoshihiro"},{"name":"Yamagami Hiroki"},{"name":"答島 章公"},{"name":"Aihara Ken-ichi"},{"name":"滝下 誠"}],"ja":[{"name":"堀 太貴"},{"name":"中村 信元"},{"name":"谷 彰浩"},{"name":"細木 美苗"},{"name":"安井 沙耶"},{"name":"宮田 好裕"},{"name":"山上 紘規"},{"name":"答島 章公"},{"name":"粟飯原 賢一"},{"name":"滝下 誠"}]},"event":{"en":"第119回日本内科学会総会","ja":"第119回日本内科学会総会"},"publication_date":"2022-04-17","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:13, {"insert":{"user_id":"B000341201","type":"presentations","id":"36577028"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384840","label":"url"}],"presentation_title":{"en":"65歳以上の透析患者における新型コロナワクチン抗体価の検討","ja":"65歳以上の透析患者における新型コロナワクチン抗体価の検討"},"presenters":{"en":[{"name":"辻 誠士郎"},{"name":"Yoshida Sumiko"},{"name":"宮 恵子"},{"name":"島久 登"},{"name":"田代 学"},{"name":"井上 朋子"},{"name":"水口 潤"},{"name":"Nakamura Shingen"},{"name":"Endo Itsuro"},{"name":"Abe Masahiro"}],"ja":[{"name":"辻 誠士郎"},{"name":"吉田 守美子"},{"name":"宮 恵子"},{"name":"島久 登"},{"name":"田代 学"},{"name":"井上 朋子"},{"name":"水口 潤"},{"name":"中村 信元"},{"name":"遠藤 逸朗"},{"name":"安倍 正博"}]},"event":{"en":"第33回日本老年医学会四国地方会","ja":"第33回日本老年医学会四国地方会"},"publication_date":"2022-01-23","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:14, {"insert":{"user_id":"B000341201","type":"presentations","id":"39550752"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388261","label":"url"}],"presentation_title":{"en":"血管中心性に浸潤し急速な経過で死に至った末梢性T細胞リンパ腫の1剖検例","ja":"血管中心性に浸潤し急速な経過で死に至った末梢性T細胞リンパ腫の1剖検例"},"presenters":{"en":[{"name":"Hori Taiki"},{"name":"Nakamura Shingen"},{"name":"Hosoki Minae"},{"name":"Yasui Saya"},{"name":"Yamagami Hiroki"},{"name":"滝下 誠"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"堀 太貴"},{"name":"中村 信元"},{"name":"細木 美苗"},{"name":"安井 沙耶"},{"name":"山上 紘規"},{"name":"滝下 誠"},{"name":"粟飯原 賢一"}]},"event":{"en":"第125回日本内科学会四国地方会","ja":"第125回日本内科学会四国地方会"},"publication_date":"2021-12-05","languages":["jpn"],"location":{"en":"web","ja":"web"},"is_international_presentation":false},"priority":"input_data"}
line:15, {"insert":{"user_id":"B000341201","type":"presentations","id":"32804661"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375944","label":"url"}],"presentation_title":{"en":"アブスコパル効果を示した甲状腺原発形質細胞腫の1例","ja":"アブスコパル効果を示した甲状腺原発形質細胞腫の1例"},"presenters":{"en":[{"name":"庄野 隆志"},{"name":"Aoyama Mariko"},{"name":"南城 和正"},{"name":"山本 清成"},{"name":"Maki Hidenori"},{"name":"Inui Tomohiro"},{"name":"Sakamoto Shinichi"},{"name":"Kobayashi Tomoko"},{"name":"Nakamura Shingen"},{"name":"Takizawa Hiromitsu"},{"name":"Tangoku Akira"}],"ja":[{"name":"庄野 隆志"},{"name":"青山 万理子"},{"name":"南城 和正"},{"name":"山本 清成"},{"name":"牧 秀則"},{"name":"乾 友浩"},{"name":"坂本 晋一"},{"name":"小林 智子"},{"name":"中村 信元"},{"name":"滝沢 宏光"},{"name":"丹黒 章"}]},"event":{"en":"第33回日本内分泌外科学会総会","ja":"第33回日本内分泌外科学会総会"},"publication_date":"2021-06-03","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:16, {"insert":{"user_id":"B000341201","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378615","label":"url"}],"presentation_title":{"en":"糖尿病患者における歩行速度規定臨床因子の解析","ja":"糖尿病患者における歩行速度規定臨床因子の解析"},"presenters":{"en":[{"name":"Kaneko Yohsuke"},{"name":"Yasui Saya"},{"name":"Yamagami Hiroki"},{"name":"Hori Taiki"},{"name":"Nakamura Shingen"},{"name":"Taniguchi Tatsuya"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Soeki Takeshi"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"金子 遥祐"},{"name":"安井 沙耶"},{"name":"山上 紘規"},{"name":"堀 太貴"},{"name":"中村 信元"},{"name":"谷口 達哉"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"添木 武"},{"name":"粟飯原 賢一"}]},"event":{"en":"第64回日本糖尿病学会年次学術集会","ja":"第64回日本糖尿病学会年次学術集会"},"publication_date":"2021-05-22","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:17, {"insert":{"user_id":"B000341201","type":"presentations","id":"33312413"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378613","label":"url"}],"presentation_title":{"en":"生体電気インピーダンス法による細胞外水分比および位相角と糖尿病患者における血中HbおよびHtレベルの連関解析","ja":"生体電気インピーダンス法による細胞外水分比および位相角と糖尿病患者における血中HbおよびHtレベルの連関解析"},"presenters":{"en":[{"name":"Aihara Ken-ichi"},{"name":"Hori Taiki"},{"name":"Yamagami Hiroki"},{"name":"Yasui Saya"},{"name":"Kaneko Yohsuke"},{"name":"Nakamura Shingen"},{"name":"Taniguchi Tatsuya"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Soeki Takeshi"},{"name":"Abe Masahiro"}],"ja":[{"name":"粟飯原 賢一"},{"name":"堀 太貴"},{"name":"山上 紘規"},{"name":"安井 沙耶"},{"name":"金子 遥祐"},{"name":"中村 信元"},{"name":"谷口 達哉"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"添木 武"},{"name":"安倍 正博"}]},"event":{"en":"第64回日本糖尿病学会年次学術集会","ja":"第64回日本糖尿病学会年次学術集会"},"publication_date":"2021-05-22","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:18, {"insert":{"user_id":"B000341201","type":"presentations","id":"33312414"},"force":{"see_also":[{"@id":"http://search.jamas.or.jp/link/ui/V617251394","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378616","label":"url"}],"presentation_title":{"en":"糖尿病患者におけるDehydroepiandrosterone sulfate(DHEAS)の糖尿病性腎臓病進展および高血圧症罹患における意義","ja":"糖尿病患者におけるDehydroepiandrosterone sulfate(DHEAS)の糖尿病性腎臓病進展および高血圧症罹患における意義"},"presenters":{"en":[{"name":"Yamagami Hiroki"},{"name":"Yasui Saya"},{"name":"Kaneko Yohsuke"},{"name":"Hori Taiki"},{"name":"Nakamura Shingen"},{"name":"Taniguchi Tatsuya"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Soeki Takeshi"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"山上 紘規"},{"name":"安井 沙耶"},{"name":"金子 遥祐"},{"name":"堀 太貴"},{"name":"中村 信元"},{"name":"谷口 達哉"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"添木 武"},{"name":"粟飯原 賢一"}]},"event":{"en":"Journal of the The Japan Diabetes Society","ja":"糖尿病"},"publication_date":"2021-05-21","languages":["jpn"],"promoter":{"en":"(一社)日本糖尿病学会","ja":"(一社)日本糖尿病学会"},"is_international_presentation":false},"priority":"input_data"}
line:19, {"insert":{"user_id":"B000341201","type":"presentations","id":"33312415"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378614","label":"url"}],"presentation_title":{"en":"糖尿病患者における非アルコール性脂肪肝疾患および骨格筋異常症におけるDehydroepiandrosterone sulfate (DHEAS)の意義","ja":"糖尿病患者における非アルコール性脂肪肝疾患および骨格筋異常症におけるDehydroepiandrosterone sulfate (DHEAS)の意義"},"presenters":{"en":[{"name":"Yasui Saya"},{"name":"Yamagami Hiroki"},{"name":"Kaneko Yohsuke"},{"name":"Hori Taiki"},{"name":"Nakamura Shingen"},{"name":"Taniguchi Tatsuya"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Soeki Takeshi"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"安井 沙耶"},{"name":"山上 紘規"},{"name":"金子 遥祐"},{"name":"堀 太貴"},{"name":"中村 信元"},{"name":"谷口 達哉"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"添木 武"},{"name":"粟飯原 賢一"}]},"event":{"en":"第64回日本糖尿病学会年次学術集会","ja":"第64回日本糖尿病学会年次学術集会"},"publication_date":"2021-05-20","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:20, {"insert":{"user_id":"B000341201","type":"presentations","id":"33352911"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388262","label":"url"}],"presentation_title":{"en":"腫大リンパ節に著明なアミロイド沈着を認めたリンパ形質細胞性リンパ腫の1例","ja":"腫大リンパ節に著明なアミロイド沈着を認めたリンパ形質細胞性リンパ腫の1例"},"presenters":{"en":[{"name":"Hori Taiki"},{"name":"Nakamura Shingen"},{"name":"Hosoki Minae"},{"name":"Yasui Saya"},{"name":"Yamagami Hiroki"},{"name":"滝下 誠"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"堀 太貴"},{"name":"中村 信元"},{"name":"細木 美苗"},{"name":"安井 沙耶"},{"name":"山上 紘規"},{"name":"滝下 誠"},{"name":"粟飯原 賢一"}]},"event":{"en":"第124回日本内科学会四国地方会","ja":"第124回日本内科学会四国地方会"},"publication_date":"2021-05-09","languages":["jpn"],"location":{"en":"web","ja":"web"},"is_international_presentation":false},"priority":"input_data"}
line:21, {"insert":{"user_id":"B000341201","type":"presentations","id":"33322274"},"force":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/2021212167","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378627","label":"url"}],"presentation_title":{"en":"生体電気インピーダンス法による細胞外水分比および位相角は糖尿病患者の血中HbおよびHtレベルを規定する","ja":"生体電気インピーダンス法による細胞外水分比および位相角は糖尿病患者の血中HbおよびHtレベルを規定する"},"presenters":{"en":[{"name":"Hori Taiki"},{"name":"Yamagami Hiroki"},{"name":"Yasui Saya"},{"name":"Kaneko Yohsuke"},{"name":"Nakamura Shingen"},{"name":"Taniguchi Tatsuya"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Soeki Takeshi"},{"name":"Abe Masahiro"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"堀 太貴"},{"name":"山上 紘規"},{"name":"安井 沙耶"},{"name":"金子 遥祐"},{"name":"中村 信元"},{"name":"谷口 達哉"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"添木 武"},{"name":"安倍 正博"},{"name":"粟飯原 賢一"}]},"event":{"en":"Folia endocrinologica Japonica","ja":"日本内分泌学会雑誌"},"publication_date":"2021-04-22","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:22, {"insert":{"user_id":"B000341201","type":"presentations","id":"33322275"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378625","label":"url"}],"presentation_title":{"en":"Dehydroepiandrosterone sulfate (DHEAS)高値は糖尿病性腎臓病進展および高血圧症罹患のリスクとなる","ja":"Dehydroepiandrosterone sulfate (DHEAS)高値は糖尿病性腎臓病進展および高血圧症罹患のリスクとなる"},"presenters":{"en":[{"name":"Yamagami Hiroki"},{"name":"Yasui Saya"},{"name":"Kaneko Yohsuke"},{"name":"Hori Taiki"},{"name":"Nakamura Shingen"},{"name":"Taniguchi Tatsuya"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Soeki Takeshi"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"山上 紘規"},{"name":"安井 沙耶"},{"name":"金子 遥祐"},{"name":"堀 太貴"},{"name":"中村 信元"},{"name":"谷口 達哉"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"添木 武"},{"name":"粟飯原 賢一"}]},"event":{"en":"第94回日本内分泌学会学術総会","ja":"第94回日本内分泌学会学術総会"},"publication_date":"2021-04-22","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:23, {"insert":{"user_id":"B000341201","type":"presentations"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378622","label":"url"}],"presentation_title":{"en":"生活習慣病患者の歩行速度は骨格筋量よりも筋力が規定する","ja":"生活習慣病患者の歩行速度は骨格筋量よりも筋力が規定する"},"presenters":{"en":[{"name":"Kaneko Yohsuke"},{"name":"Yasui Saya"},{"name":"Yamagami Hiroki"},{"name":"Hori Taiki"},{"name":"Nakamura Shingen"},{"name":"Taniguchi Tatsuya"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Soeki Takeshi"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"金子 遥祐"},{"name":"安井 沙耶"},{"name":"山上 紘規"},{"name":"堀 太貴"},{"name":"中村 信元"},{"name":"谷口 達哉"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"添木 武"},{"name":"粟飯原 賢一"}]},"event":{"en":"第94回日本内分泌学会学術総会","ja":"第94回日本内分泌学会学術総会"},"publication_date":"2021-04-22","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:24, {"insert":{"user_id":"B000341201","type":"presentations","id":"33352923"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=388263","label":"url"}],"presentation_title":{"en":"アミカシンによるAPTT偽延長を来したSerratia marcescens菌血症の1例","ja":"アミカシンによるAPTT偽延長を来したSerratia marcescens菌血症の1例"},"presenters":{"en":[{"name":"Kaneko Yohsuke"},{"name":"Nakamura Shingen"},{"name":"Hosoki Minae"},{"name":"Yasui Saya"},{"name":"Yamagami Hiroki"},{"name":"Hori Taiki"},{"name":"滝下 誠"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"金子 遥祐"},{"name":"中村 信元"},{"name":"細木 美苗"},{"name":"安井 沙耶"},{"name":"山上 紘規"},{"name":"堀 太貴"},{"name":"滝下 誠"},{"name":"粟飯原 賢一"}]},"event":{"en":"第123回日本内科学会四国地方会","ja":"第123回日本内科学会四国地方会"},"publication_date":"2020-11-12","languages":["jpn"],"location":{"en":"web","ja":"web"},"is_international_presentation":false},"priority":"input_data"}
line:25, {"insert":{"user_id":"B000341201","type":"presentations","id":"33312416"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378611","label":"url"}],"presentation_title":{"en":"当院生活習慣病患者における握力と歩行速度に影響を与える因子の検討","ja":"当院生活習慣病患者における握力と歩行速度に影響を与える因子の検討"},"presenters":{"en":[{"name":"Yamagami Hiroki"},{"name":"Yasui Saya"},{"name":"Kaneko Yohsuke"},{"name":"Hori Taiki"},{"name":"Nakamura Shingen"},{"name":"Taniguchi Tatsuya"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Soeki Takeshi"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"山上 紘規"},{"name":"安井 沙耶"},{"name":"金子 遥祐"},{"name":"堀 太貴"},{"name":"中村 信元"},{"name":"谷口 達哉"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"添木 武"},{"name":"粟飯原 賢一"}]},"event":{"en":"第20回日本内分泌学会四国支部学術集会","ja":"第20回日本内分泌学会四国支部学術集会"},"publication_date":"2020-09-12","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:26, {"insert":{"user_id":"B000341201","type":"presentations","id":"33312417"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378610","label":"url"}],"presentation_title":{"en":"当院生活習慣病患者における骨格筋量に影響を与える因子の検討","ja":"当院生活習慣病患者における骨格筋量に影響を与える因子の検討"},"presenters":{"en":[{"name":"Yasui Saya"},{"name":"Yamagami Hiroki"},{"name":"Kaneko Yohsuke"},{"name":"Hori Taiki"},{"name":"Nakamura Shingen"},{"name":"Taniguchi Tatsuya"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Soeki Takeshi"},{"name":"Aihara Ken-ichi"}],"ja":[{"name":"安井 沙耶"},{"name":"山上 紘規"},{"name":"金子 遥祐"},{"name":"堀 太貴"},{"name":"中村 信元"},{"name":"谷口 達哉"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"添木 武"},{"name":"粟飯原 賢一"}]},"event":{"en":"第20回日本内分泌学会四国支部学術集会","ja":"第20回日本内分泌学会四国支部学術集会"},"publication_date":"2020-09-12","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:27, {"insert":{"user_id":"B000341201","type":"presentations"},"similar_merge":{"see_also":[{"@id":"http://search.jamas.or.jp/link/ui/2020320800","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=379409","label":"url"}],"presentation_title":{"en":"機械学習を用いたゲノム情報によるシタラビン投与の副作用発現予測モデルの構築","ja":"機械学習を用いたゲノム情報によるシタラビン投与の副作用発現予測モデルの構築"},"presenters":{"en":[{"name":"遠藤 優香"},{"name":"田島 穂澄"},{"name":"Okada Naoto"},{"name":"Nakamura Shingen"},{"name":"Kagawa Kumiko"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Ishizawa Keisuke"},{"name":"Abe Masahiro"},{"name":"Sato Youichi"}],"ja":[{"name":"遠藤 優香"},{"name":"田島 穂澄"},{"name":"岡田 直人"},{"name":"中村 信元"},{"name":"賀川 久美子"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"石澤 啓介"},{"name":"安倍 正博"},{"name":"佐藤 陽一"}]},"event":{"en":"日本薬学会年会要旨集","ja":"日本薬学会年会要旨集"},"publication_date":"2020-03","languages":["jpn"],"promoter":{"en":"(公社)日本薬学会","ja":"(公社)日本薬学会"},"is_international_presentation":false},"priority":"input_data"}
line:28, {"insert":{"user_id":"B000341201","type":"presentations","id":"32804671"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353417","label":"url"}],"presentation_title":{"en":"自家末梢血幹細胞移植患者の口腔ケアによる口腔粘膜炎障害の低減効果","ja":"自家末梢血幹細胞移植患者の口腔ケアによる口腔粘膜炎障害の低減効果"},"presenters":{"en":[{"name":"Sogawa Yuka"},{"name":"Yoshioka Masami"},{"name":"南 明香"},{"name":"Fukui Makoto"},{"name":"Hinode Daisuke"},{"name":"Nakamura Shingen"},{"name":"Abe Masahiro"}],"ja":[{"name":"十川 悠香"},{"name":"吉岡 昌美"},{"name":"南 明香"},{"name":"福井 誠"},{"name":"日野出 大輔"},{"name":"中村 信元"},{"name":"安倍 正博"}]},"event":{"en":"第68回日本口腔衛生学会総会","ja":"第68回日本口腔衛生学会総会"},"publication_date":"2019-05-22","languages":["jpn"],"is_international_presentation":false},"priority":"input_data"}
line:29, {"insert":{"user_id":"B000341201","type":"presentations","id":"32804685"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=343461","label":"url"}],"presentation_title":{"en":"骨形成誘導による骨髄腫細胞のエネルギー代謝の抑制","ja":"骨形成誘導による骨髄腫細胞のエネルギー代謝の抑制"},"presenters":{"en":[{"name":"天知 良太"},{"name":"Nakamura Shingen"},{"name":"Hiasa Masahiro"},{"name":"小田 明日香"},{"name":"バットエルデネ アリウンザヤ"},{"name":"Teramachi Jumpei"},{"name":"Tenshin Hirofumi"},{"name":"Watanabe Keiichiro"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Fujii Shiroh"},{"name":"Tanaka Eiji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"天知 良太"},{"name":"中村 信元"},{"name":"日浅 雅博"},{"name":"小田 明日香"},{"name":"バットエルデネ アリウンザヤ"},{"name":"寺町 順平"},{"name":"天眞 寛文"},{"name":"渡邉 佳一郎"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"藤井 志朗"},{"name":"田中 栄二"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"event":{"en":"第42回日本骨髄腫学会学術集会","ja":"第42回日本骨髄腫学会学術集会"},"publication_date":"2017-05-27","languages":["jpn"],"promoter":{"en":"日本骨髄腫学会","ja":"日本骨髄腫学会"},"location":{"en":"日本赤十字看護大学 広尾キャンパス","ja":"日本赤十字看護大学 広尾キャンパス"},"is_international_presentation":false},"priority":"input_data"}
line:30, {"insert":{"user_id":"B000341201","type":"presentations"},"similar_merge":{"see_also":[{"@id":"http://search.jamas.or.jp/link/ui/2012111920","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=253461","label":"url"}],"presentation_title":{"en":"Pimキナーゼの阻害は骨芽細胞分化を促進し，骨髄腫骨病変の形成と腫瘍進展を抑制する","ja":"Pimキナーゼの阻害は骨芽細胞分化を促進し，骨髄腫骨病変の形成と腫瘍進展を抑制する"},"presenters":{"en":[{"name":"Hiasa Masahiro"},{"name":"Abe Masahiro"},{"name":"中野 綾子"},{"name":"Watanabe Keiichiro"},{"name":"Nakamura Shingen"},{"name":"Tanaka Eiji"},{"name":"Asaoka Kenzo"},{"name":"Matsumoto Toshio"}],"ja":[{"name":"日浅 雅博"},{"name":"安倍 正博"},{"name":"中野 綾子"},{"name":"渡邉 佳一郎"},{"name":"中村 信元"},{"name":"田中 栄二"},{"name":"淺岡 憲三"},{"name":"松本 俊夫"}]},"event":{"en":"The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts","ja":"日本骨代謝学会学術集会プログラム抄録集"},"publication_date":"2011-07-28","languages":["jpn"],"promoter":{"en":"第29回日本骨代謝学会学術大会","ja":"第29回日本骨代謝学会学術大会"},"location":{"en":"Osaka","ja":"大阪"},"is_international_presentation":false},"priority":"input_data"}
line:31, {"insert":{"user_id":"B000341201","type":"presentations"},"similar_merge":{"see_also":[{"@id":"http://search.jamas.or.jp/link/ui/2012111981","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=253460","label":"url"}],"presentation_title":{"en":"リベロマイシンAによる酸性環境がもたらす骨髄腫薬剤耐性の克服と骨病変形成の抑制","ja":"リベロマイシンAによる酸性環境がもたらす骨髄腫薬剤耐性の克服と骨病変形成の抑制"},"presenters":{"en":[{"name":"Watanabe Keiichiro"},{"name":"Abe Masahiro"},{"name":"川谷 誠"},{"name":"Hiasa Masahiro"},{"name":"Nakamura Shingen"},{"name":"Tanaka Eiji"},{"name":"長田 裕之"},{"name":"Matsumoto Toshio"}],"ja":[{"name":"渡邉 佳一郎"},{"name":"安倍 正博"},{"name":"川谷 誠"},{"name":"日浅 雅博"},{"name":"中村 信元"},{"name":"田中 栄二"},{"name":"長田 裕之"},{"name":"松本 俊夫"}]},"event":{"en":"The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts","ja":"日本骨代謝学会学術集会プログラム抄録集"},"publication_date":"2011-07-28","languages":["jpn"],"promoter":{"en":"第29回日本骨代謝学会学術大会","ja":"第29回日本骨代謝学会学術大会"},"location":{"en":"Osaka","ja":"大阪"},"is_international_presentation":false},"priority":"input_data"}
==== end registerFile(/WWW/pub2/data/ERD/person/229265/researchmap/presentations-propagate.jsonl, E6AgrKABn_HdSsNV2xa3) ====
====== BulkResult(B000341201, E6AgrKABn_HdSsNV2xa3) : Begin ======
--- error
{"code":304,"status":"completion","start_datetime":"2026-09-16T21:30:38Z","end_datetime":"2026-09-16T21:30:38Z","estimated_end_datetime":"2026-09-16T21:30:39Z","total_items":31}

--- success
{"code":304,"status":"completion","start_datetime":"2026-09-16T21:30:38Z","end_datetime":"2026-09-16T21:30:38Z","estimated_end_datetime":"2026-09-16T21:30:39Z","total_items":31}
{"no":1,"line":1,"code":304,"action":"insert","action_type":"force","type":"presentations","id":"1738077","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/1738077","messages":[{"code":304,"message":"not_modified","message_description":"本人相当が登録した既存データが存在したため、更新しませんでした[id=1738077]。"}]}
{"no":1,"line":2,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"47364782","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/47364782","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =47364782]。"}]}
{"no":1,"line":3,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"47364783","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/47364783","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =47364783]。"}]}
{"no":1,"line":4,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"47364784","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/47364784","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =47364784]。"}]}
{"no":1,"line":5,"code":200,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","id":"43213469","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/43213469"}
{"no":1,"line":6,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"39550744","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/39550744","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =39550744]。"}]}
{"no":1,"line":7,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"39550746","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/39550746","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =39550746]。"}]}
{"no":1,"line":8,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"39550747","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/39550747","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =39550747]。"}]}
{"no":1,"line":9,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"39550748","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/39550748","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =39550748]。"}]}
{"no":1,"line":10,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"39550749","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/39550749","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =39550749]。"}]}
{"no":1,"line":11,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"39550750","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/39550750","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =39550750]。"}]}
{"no":1,"line":12,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"39550751","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/39550751","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =39550751]。"}]}
{"no":1,"line":13,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"36577028","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/36577028","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =36577028]。"}]}
{"no":1,"line":14,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"39550752","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/39550752","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =39550752]。"}]}
{"no":1,"line":15,"code":304,"action":"insert","action_type":"force","type":"presentations","id":"32804661","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/32804661","messages":[{"code":304,"message":"not_modified","message_description":"本人相当が登録した既存データが存在したため、更新しませんでした[id=32804661]。"}]}
{"no":1,"line":16,"code":200,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","id":"33312412","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/33312412"}
{"no":1,"line":17,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"33312413","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/33312413","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =33312413]。"}]}
{"no":1,"line":18,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"33312414","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/33312414","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =33312414]。"}]}
{"no":1,"line":19,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"33312415","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/33312415","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =33312415]。"}]}
{"no":1,"line":20,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"33352911","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/33352911","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =33352911]。"}]}
{"no":1,"line":21,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"33322274","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/33322274","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =33322274]。"}]}
{"no":1,"line":22,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"33322275","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/33322275","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =33322275]。"}]}
{"no":1,"line":23,"code":200,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","id":"33322276","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/33322276"}
{"no":1,"line":24,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"33352923","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/33352923","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =33352923]。"}]}
{"no":1,"line":25,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"33312416","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/33312416","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =33312416]。"}]}
{"no":1,"line":26,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"33312417","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/33312417","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =33312417]。"}]}
{"no":1,"line":27,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","id":"32804665","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/32804665","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=32804665]。"}]}
{"no":1,"line":28,"code":304,"action":"insert","action_type":"force","type":"presentations","id":"32804671","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/32804671","messages":[{"code":304,"message":"not_modified","message_description":"本人相当が登録した既存データが存在したため、更新しませんでした[id=32804671]。"}]}
{"no":1,"line":29,"code":304,"action":"insert","action_type":"force","type":"presentations","id":"32804685","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/32804685","messages":[{"code":304,"message":"not_modified","message_description":"本人相当が登録した既存データが存在したため、更新しませんでした[id=32804685]。"}]}
{"no":1,"line":30,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","id":"1738093","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/1738093","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=1738093]。"}]}
{"no":1,"line":31,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"presentations","id":"1738094","link":"https://api.researchmap.jp/zxcvbnm-2/presentations/1738094","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=1738094]。"}]}
====== BulkResult(B000341201, E6AgrKABn_HdSsNV2xa3) : End ======
====== BulkResult(B000341201, KsYgrKABRJbN-uhaijxc) : Begin ======
--- error
{"code":304,"status":"completion","start_datetime":"2026-09-16T21:30:12Z","end_datetime":"2026-09-16T21:30:13Z","estimated_end_datetime":"2026-09-16T21:30:13Z","total_items":29}

--- success
{"code":304,"status":"completion","start_datetime":"2026-09-16T21:30:12Z","end_datetime":"2026-09-16T21:30:13Z","estimated_end_datetime":"2026-09-16T21:30:13Z","total_items":29}
{"no":1,"line":1,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"48573526","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/48573526","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=48573526]。"}]}
{"no":1,"line":2,"code":304,"action":"insert","action_type":"merge","type":"published_papers","id":"47364775","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/47364775","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =47364775]。"}]}
{"no":1,"line":3,"code":304,"action":"insert","action_type":"merge","type":"published_papers","id":"46782334","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/46782334","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =46782334]。"}]}
{"no":1,"line":4,"code":304,"action":"insert","action_type":"merge","type":"published_papers","id":"47364776","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/47364776","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =47364776]。"}]}
{"no":1,"line":5,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"46186464","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/46186464","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=46186464]。"}]}
{"no":1,"line":6,"code":200,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"47364777","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/47364777"}
{"no":1,"line":7,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"42953170","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/42953170","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=42953170]。"}]}
{"no":1,"line":8,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"40107350","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/40107350","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=40107350]。"}]}
{"no":1,"line":9,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"41281517","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/41281517","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=41281517]。"}]}
{"no":1,"line":10,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"38753846","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/38753846","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=38753846]。"}]}
{"no":1,"line":11,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"37854954","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/37854954","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=37854954]。"}]}
{"no":1,"line":12,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"37663004","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/37663004","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=37663004]。"}]}
{"no":1,"line":13,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"35163656","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/35163656","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=35163656]。"}]}
{"no":1,"line":14,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"29515115","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/29515115","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=29515115]。"}]}
{"no":1,"line":15,"code":304,"action":"insert","action_type":"merge","type":"published_papers","id":"32804690","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/32804690","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =32804690]。"}]}
{"no":1,"line":16,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"26416731","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/26416731","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=26416731]。"}]}
{"no":1,"line":17,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","id":"11921865","link":"https://api.researchmap.jp/zxcvbnm-2/misc/11921865","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=11921865]。"}]}
{"no":1,"line":18,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","id":"11921866","link":"https://api.researchmap.jp/zxcvbnm-2/misc/11921866","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=11921866]。"}]}
{"no":1,"line":19,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","id":"11921869","link":"https://api.researchmap.jp/zxcvbnm-2/misc/11921869","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=11921869]。"}]}
{"no":1,"line":20,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","id":"11921867","link":"https://api.researchmap.jp/zxcvbnm-2/misc/11921867","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=11921867]。"}]}
{"no":1,"line":21,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","id":"11921868","link":"https://api.researchmap.jp/zxcvbnm-2/misc/11921868","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=11921868]。"}]}
{"no":1,"line":22,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","id":"11921870","link":"https://api.researchmap.jp/zxcvbnm-2/misc/11921870","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=11921870]。"}]}
{"no":1,"line":23,"code":304,"action":"insert","action_type":"force","type":"published_papers","id":"15167274","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/15167274","messages":[{"code":304,"message":"not_modified","message_description":"本人相当が登録した既存データが存在したため、更新しませんでした[id=15167274]。"}]}
{"no":1,"line":24,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","id":"11921872","link":"https://api.researchmap.jp/zxcvbnm-2/misc/11921872","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=11921872]。"}]}
{"no":1,"line":25,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","id":"11921871","link":"https://api.researchmap.jp/zxcvbnm-2/misc/11921871","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=11921871]。"}]}
{"no":1,"line":26,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"15167276","link":"https://api.researchmap.jp/zxcvbnm-2/published_papers/15167276","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=15167276]。"}]}
{"no":1,"line":27,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","id":"11921874","link":"https://api.researchmap.jp/zxcvbnm-2/misc/11921874","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=11921874]。"}]}
{"no":1,"line":28,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","id":"11921875","link":"https://api.researchmap.jp/zxcvbnm-2/misc/11921875","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=11921875]。"}]}
{"no":1,"line":29,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"misc","id":"11921873","link":"https://api.researchmap.jp/zxcvbnm-2/misc/11921873","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=11921873]。"}]}
====== BulkResult(B000341201, KsYgrKABRJbN-uhaijxc) : End ======